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EVALUATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR
SIGNALING PATHWAY AS A THERAPEUTIC TARGET IN
HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE
by
Anastacia Maria Griego
B.S., Biology, University of New Mexico, 2007
Ph.D., Biomedical Sciences, University of New Mexico, 2016
ABSTRACT
Human papillomaviruses (HPVs) are the most common sexually transmitted infectious
agents. They are responsible for >99% of all cervical cancers as well as subsets of other
anogenital cancers. HPVs are also the causative agents of a growing number of head and
neck cancers.

As such, they present a significant health problem both in the U.S. and

developing countries.

Much is still unknown regarding the factors underlying

progression from HPV infection to cancer or maintenance of viral oncoprotein expression
following oncogenic transformation.
Previous studies reported significant interplay between the epidermal growth
factor (EGFR) pathway and HPV oncoproteins. HPV oncoproteins E5, E6, and E7 have
been implicated in upregulation of EGFR signaling and expression.

Additionally,

downstream effectors of EGFR signaling were shown to upregulate HPV early gene
expression. These reports led us to hypothesize that, in infected cells, HPV establishes a
positive feedback loop with the EGFR pathway, wherein viral proteins upregulate EGFR
signaling, which then leads to enhanced viral oncogene expression.

We further

postulated that interruption of this feedback loop, via inhibitors of the EGFR signaling
vi

pathway, would result in decreased viral oncoprotein levels and increased sensitivity to
apoptotic stimuli.
In a model of early, persistent infection, we found that EGFR signaling modulated
HPV early gene expression, including upregulation of viral oncogene expression upon
EGFR stimulation. We discovered that EGFR inhibition by cetuximab, a monoclonal
antibody targeting EGFR, had antiviral effects including downregulation of HPV
oncogene expression levels in this model. Furthermore, in cells harboring episomal viral
genomes, inhibition of this pathway led to reduced viral genome burden and sensitization
to apoptotic stimuli.
Our study further reveals that EGFR/MEK inhibition can lead to downregulation
of HPV oncogene expression in vivo, in subsets of HPV-positive xenografts, concomitant
with delayed tumor growth. These results suggest a possible role for antiviral effects in
the therapeutic outcomes observed following EGFR-inhibitor treatment of HPVassociated diseases in the clinic. Together, these data indicate that use of EGFR/MEK
inhibitors may be beneficial in the treatment of HPV-associated diseases. Furthermore,
the results of this study set the frame work to better understand the role of growth factor
signaling in the HPV lifecycle.
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CHAPTER 1 - Introduction
1.1 History of Viruses and Cancer
The discovery of a transferable oncogenic agent in cell-free tumor lysates by Ellerman
and Bang in 1908 ushered in a new era in cancer research [1]. The causative infectious
agent was later identified as the oncogenic retrovirus, avian sarcoma leukosis virus
(ASLV). Subsequent to this initial discovery, multiple DNA and retroviruses have been
found to be associated with carcinogenesis, both in animals and humans. The discovery
of another transmissible filterable agent, Rous Sarcoma Virus (RSV), in 1911 by Peyton
Rous, eventually led to the identification of the viral oncogene src by other groups [2, 3].
Rous received a Nobel Prize in Physiology or Medicine for his work. This paved the way
to the discovery of the first cellular proto-oncogene, c-src, for which Bishop and Varmus
shared the Nobel Prize in Physiology or Medicine in 1989 [4]. In the following years,
additional viruses including retroviruses (MMTV, HTLV-1) herpesviruses (KSV, EBV),
polyomaviruses (SV40, MCV), hepadnaviruses (HBV, HCV), adenoviruses (Ad2, Ad5),
and papillomaviruses (e.g. HPV16, -18, -31) have been associated with cancer or shown
to have transforming abilities in vitro.
The strongest link between viruses and human cancer is the relationship between
infection with certain types of HPV and cervical cancer as shown by H. zur Hausen in the
late 1970’s. HPV is the causative agent of nearly 100% of cervical cancers as well as a
number of other anogenital and head and neck cancers [5-7]. For his work identifying
HPV as a causative agent of cervical cancers, zur Hausen was awarded a Nobel Prize in
2008.
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While oncovirus research has provided a wealth of information about
carcinogenesis, targeting the causative infectious agents to reduce cancer burden has
proven difficult. In the case of HPV, there are currently three highly effective vaccines
available. However, vaccine coverage remains low and the current vaccines offer no
therapeutic protection for individuals already infected with the most common oncogenic
HPV types. Additionally, many of the individuals at the greatest risk of developing
HPV-associated cancers do not have access to the vaccine [8].

1.2 HPV Types and Infection
Papillomaviruses (PVs) are small, non-enveloped, icosahedral viruses encapsidating a
circular double-stranded DNA genome of approximately 8 kilobases (Fig 1.1). The
Family Papillomaviridae is comprised of hundreds of species, divided into 39 genera
based on species and tissue specificity; PVs that infect humans (HPVs) are found in five
of these genera. Over 150 genotypes of HPV have been sequenced (see [9, 10] and
Papillomavirus Episteme (PaVE); http://pave.niaid.nih.gov/#home).

HPVs exhibit

specific tropism for either cutaneous or mucosal squamous epithelium, with members of
the Beta PV genus primarily infecting the former and Alpha PVs responsible for
infections of the mucosa [10]. Tropism is thought to be controlled at the level of gene
expression though regulatory elements in the viral long control region (LCR) [11]. All
PVs cause either benign or malignant hyperplasia and are thus divided into low- and
high-risk types depending on the probability of infection progressing to malignancy [10].

2

Figure 1.1 TEM image of HPV particles
A transmission electron micrograph (TEM) of negatively stained pseudovirus particles composed of
HPV16 L1 and L2 proteins showing the icosahedral form of the viral capsid. Capsomeres, each composed
of five L1 proteins, can be seen. Blue bar represents 100nm. Image was generated by A. Griego using the
UNM Electron Microscopy Shared Facility supported by the University of New Mexico Health Sciences
Center.

1.3 HPV Lifecycle and Replication
HPVs establish infections in the basal cells of stratified squamous epithelium, to which
they gain access through a wound or break in the overlying epidermal layers (Fig 1.2)
[12, 13]. Following entry of the virus into a host cell, viral genomes are amplified and
infection is established. HPVs exhibit a differentiation dependent lifecycle wherein
temporal expression of viral genes is regulated by the host cell differentiation process,
therefore, a productive infection can only occur in stratified epithelium [11, 14-16].

3

Figure 1.2 The lifecycle of papillomaviruses.
Papillomaviruses infect the basal layer of the epidermis through a break, or wound, in the upper layers.
Upon infection, viral genomes are replicated and maintained at low levels; early viral gene expression is
kept tightly regulated. As basal cells divide, viral genomes are distributed to each daughter cell. As
infected daughter cells differentiate and enter the spinous layer, expression of viral early genes is increased
to enable enhanced proliferation of the cell and facilitate amplification of viral genomes. Downregulation
of viral early gene expression and expression of late viral proteins, which compose the viral capsid, occurs
in the granular layer, wherein virion assembly occurs. Release of viral particles occurs upon sloughing off
of the cornified layer of the epidermis. Adapted from [17].
!
!
!
!

!

Viral proteins E1 and E2 are essential for replication of the viral genome and

maintenance of infection. E1 is the only enzyme produced by HPVs and serves as the
essential DNA helicase for viral DNA replication [18]. E2 has multiple binding sites in
the LCR and recruits E1 to initiate viral genome replication [19, 20]. In addition to its
role in recruiting E1 to the origin of replication, E2 also facilitates maintenance of
infection. During cellular division, viral protein E2, in association with cellular protein
bromodomain-4 (BRD4), attaches viral genomes to host mitotic chromosomes allowing
distribution of viral genomes between daughter cells, further propagating infection [2123]. Other E2 binding partners are also considered to have a role in division of viral
genomes [24, 25].
As the infected epithelial cells undergo early differentiation events, viral proteins
E6 and E7 are expressed and enable the cells to undergo increased proliferation by
dysregulation of cell cycle checkpoints. In the upper layers of the epithelium, viral
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genomes are amplified. Downregulation of E6 and E7 expression, reinitiation of cellular
differentiation, and expression of L1 and L2, the major and minor viral capsid proteins,
follow genome amplification respectively. L1 and L2 encapsidate newly synthesized
viral genomes, forming new infectious particles or virions. Expression of E4 is also
amplified during late infection. The E4 protein is thought to facilitate virion release by
interacting with cytokeratins and disrupting the cytoskeletal network of intermediate
filaments; this function is most apparent in cutaneous HPV genotypes [26]. Progeny
virions are spread by the sloughing off of the cornified layer of infected epithelial cells
(reviewed in [27]).

1.4 HPV Gene Expression
The circular double-stranded DNA genomes of PVs are maintained extrachromosomally
during a productive infection. HPV encodes four major early proteins (E1, E2, E6/E6*,
E7) and four to five late proteins (E4, E5a/b, L1, L2, and sometimes E8) (Fig. 3). HPV
genes are transcribed and undergo splicing to produce polycistronic RNAs [17, 20].
Control of viral gene expression is mediated by an ~800 bp stretch of DNA
between the late and early coding regions of the genome, known as the long control
region (LCR) or upstream regulatory region (URR). As previously, mentioned, the LCR
contains multiple binding sites for viral proteins E1 and E2 as well as cellular factors.
HPV early gene expression is initiated from one or more promoters located in the LCR
[28-30]. In HPV16, gene expression is controlled from two main promoters, p97 (the
early proximal promoter) and p670 (the major late promoter) [31, 32]. Viral genes are
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expressed temporally and control of their expression appears to be mediated by
differentiation-associated changes in cellular transcription factors (reviewed in [20]).

Figure 1.3 HPV16 genome organization.
Linearized representation of the alpha-papillomavirus genome organization. The LCR contains at least two
promoters, depicted here are the early and late promoters. Colored boxes represent ORFs for each gene.
Red boxes indicate the major oncogenes E6 and E7. The remaining early genes E1 and E2 as well as
intermediate-late genes E4 and E5 are depicted in blue. E8 is an intermediate-late protein that is expressed
in only a few papillomavirus genotypes. Orange boxes denote genes for major and minor capsid proteins
L1 and L2, respectively.

The early proteins, particularly E6 and E7, are important in the regulation of cellular
proliferation and differentiation.

In addition to facilitating genome replication and

maintenance of infection, E2 regulates expression of viral oncogenes E6 and E7. As E6
and E7 enhance proliferation and inhibit differentiation to ensure viral genome
amplification in intermediate epithelial layers, strict control of their expression is
necessary for reinitiation of cellular differentiation and completion of the viral life cycle.
Binding of E2 to the LCR near the early promoter inhibits E6 and E7 expression [33, 34].
This is thought to occur by steric hindrance of TFIID binding or recruitment of
transcriptional repressors, including Sp1 [20]. Loss of E2 expression or ability to bind to
the LCR, for example through integration into the host DNA or via DNA methylation
events, is thought to be important in the progression of lesions to cancer [35-38].
6

1.5 HPV Oncoproteins
High-risk HPVs encode three oncoproteins: E5, E6 and E7. These proteins are produced
early in the viral lifecycle and expression is kept under strict viral control. E6 and E7 are
the best studied of these proteins and are expressed at high levels in HPV-associated
cancers.

E6 and E7 are each capable of causing immortalization when ectopically

overexpressed in vitro [39-42].

Figure 1.4 HPV oncoproteins E6 and E7 target p53 and pRb for degradation.
HPV infection results in loss of normal cell cycle control and increased cellular proliferation. E6 degrades
p53 resulting in loss of p21 upregulation. Additionally, E7 can degrade remaining p21, resulting in
downregulation of p21 protein levels. Levels of p16 are elevated in HPV-positive cancers due to
degradation of pRb.
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The most well-known function of E6 is degradation of the tumor suppressor
protein, p53 (Fig 1.4) [43, 44]. E6 interacts with the cellular protein E6-associated
protein (E6AP, also known as UBE3A), an ubiquitin protein-ligase.

The E6-E6AP

complex then binds cellular p53 [45]. p53 is subsequently ubiquitinated and degraded
through the proteasomal pathway. Loss of p53 in cells results in dysregulation of cell
cycle checkpoints and allows infected cells to reenter the cell cycle in the intermediate
layers of the epidermis.

The resulting hyperproliferation enables expansion of the

number of infected cells. S-phase reentry is also necessary for amplification of the viral
genome in the upper epithelial layers. E6 also interacts with numerous cellular proteins
(reviewed in [46]).

For example, E6 can the bind PDZ domain-containing cellular

proteins including, MAGI1 and MUPP1, resulting in loss of cell polarity [47-51].
Additionally, E6-E6AP complex can facilitate cellular immortalization by activating
telomerase expression through upregulation of c-Myc expression [52-56].
The other viral protein responsible for driving cellular proliferation and enabling
S-phase reentry is E7 (Fig 1.4). E7 from high-risk HPVs functions to downregulate pRb
levels in infected cells by binding the active form of the protein and inhibiting its
interaction with the transcription factor E2F [57, 58].

E7 then directs pRb for

degradation resulting in cellular progression to S-phase [59]. The resulting increase in
free E2F transcription factor levels also augments E6-mediated telomerase expression
[55, 60, 61]. As with E6, HPV E7 interacts with numerous other cellular proteins. These
interactions are reviewed in detail by Roman and Munger [62].
E5 is the least well understood of the HPV oncoproteins. E5 from HPV16
upregulates epidermal growth factor receptor (EGFR) expression and signaling [63-68].
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The specific mechanism by which this is done is currently unknown. Studies of BPV E5
show that the viral protein directly binds the growth factor receptor, PDGFβR, and crosslinks homodimers to initiate activation of the receptor [69-71]. However, direct binding
between HPV E5 and EGFR has not been demonstrated. E5 is the only membrane
associated protein produced by HPV and Wetherill, et al. recently showed that E5 from
HPV16 is capable of forming viroporin-like structures [72]. The viroporin inhibitor
rimantidine, as well as a novel, empirically designed, E5 specific inhibitor, was reported
to decrease endosome acidification in HPV16 E5 expressing HaCaT cells and reduce E5associated ERK activation following EGF stimulation of cells. These data indicate that
HPV E5 may undertake EGFR upregulation through inhibition of early endosome
acidification resulting in recycling of the EGFR back to the cell membrane.
Although cell cycle dysregulation and heightened proliferation are necessary for
large-scale replication of the viral genome, expression of E6 and E7 must be tightly
controlled in order to reinitiate cellular differentiation and complete the viral lifecycle.
Uncontrolled E6 and E7 expression is understood to underlie oncogenic transformation of
HPV infected cells. As discussed previously, E2 inhibits expression of E6 and E7 and
loss of E2 expression or ability to bind inhibitory sites in the LCR is considered to
precede cancer development. In cancers, viral genomes can be found either episomally,
integrated into the host genome, or as a mixed population. HPV cancers typically contain
low levels of the tumor suppressor proteins p53 and pRb due to high E6 and E7
expression. Conversely, levels of the cellular protein p16 are increased as a result of pRb
loss. In fact, high p16 expression is commonly used as a biomarker for HPV-associated
cancers in the absence of genomic testing [73-76].

9

As E6 and E7 drive HPV-associated cancers, reducing levels of these proteins
should have therapeutic effects. In fact, knockdown of E6 and E7 levels in cancer cell
lines by siRNA results in increased p53 levels and apoptosis in vitro [77, 78].
Additionally, siRNA knockdown of E6 and E7 in SiHa and HeLa xenograft tumors in
vivo effected inhibition of tumor growth and increased p53 and radiosensitization [79,
80]. These reports demonstrate that reducing E6 and E7 levels in HPV-positive cancers
reduces tumor burden and may sensitize the cells to chemotherapy and radiation via
reinstatement of p53 levels.

1.6 HPV-Associated Diseases
HPVs infect cutaneous and mucosal epithelium and are associated with numerous
diseases. HPVs are responsible for over 71% of all sexually transmitted infections and
as such are the single most prevalent sexually transmitted infectious agents [81].
Transmission of HPV happens readily and 8 out of 10 sexually active women will
become infected in their lifetime. Prior to HPV vaccine program initiation in the U.S.,
there were 79 million Americans infected at any one time, with 6 million new infections
annually [81]. Since introduction of the vaccine in the U.S., rates of new infections have
decreased by half in the target group of adolescent girls. However, uptake of the vaccine
in the U.S. is still low; with only 40% of girls and <30% of boys in the target age range
receiving the recommended 3-doses of the vaccine [8].
Low-risk HPV types 6 and 11 are associated with 90% of genital and anal warts.
From 2-10% of adults in the U.S. and Europe report being diagnosed with genital warts at
sometime during their life [82]. The transmission rate of the virus types associated with
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genital warts is reported to be ~60% and transmission can occur even if visible lesions
are not present [83]. Infection with these HPV types is typically not associated with
cancer progression. Clinical intervention for these lesions includes topical treatments,
ablation, or surgical removal [84].
Recurrent respiratory papillomatosis (RRP) results from infection of the
respiratory tract with HPV, and types 6 and 11 are most commonly associated with this
disease [85]. Incidence of this condition is rare with only 4/100,000 children and half as
many adults diagnosed each year [84]. Occurrence in children can be associated with
vertical transmission of the virus from mother to child in utero or during birth. Incidence
in adults is commonly linked to sexual transmission. Papillomas frequently recur and can
cause blockage of the airways requiring medical intervention especially in young
children. Treatment for RRP includes repeated surgical removal of papillomas, resulting
in high morbidity, especially in young children. Case studies have reported beneficial
outcomes of chemotherapeutics including inhibitors of EGFR and vascular endothelial
growth factor (VEGF) inhibitors in a small number of patients [85]. A large-scale
clinical trial investigating the efficacy of cyclooxygenase-2 (COX-2) inhibitors in
controlling the disease has also been undertaken [85].
High-risk HPVs are responsible for nearly 5% of all cancers worldwide [6].
Although high-risk HPVs are commonly associated with cancer of the uterine cervix,
they also cause subset of vulvar, vaginal, penile, anal, and head and neck squamous cell
carcinomas (HSNCC) (summarized in Fig 5) [6, 82]. While the majority of infections
with high-risk HPVs are naturally cleared within 12-18 months due to effective immune
intervention, 10-20% of cases are thought to persist and develop into recurrent or
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possibly latent infections [86]. A portion of these persistent infections may progress to
cancer.
High-risk HPVs are responsible for nearly 100% of cervical cancers, with HPV
types 16 and 18 alone responsible for 70% of these cancers [5]. Cervical cancer is
currently the 3rd most common cancer in women worldwide. Although the incident
number of cases of cervical cancer has decreased by 1/3 in the U.S. since 1975 due to an
effective screening program, cervical cancer remains a substantial health burden in
developing countries [6]. Even with the decline in new cervical cancer cases in that time
period, there has not been a significant decrease in the number of cervical cancerassociated deaths. In fact, the 5-year progression-free survival has remained fairly
constant at ~70% (NCI SEER 9 Incidence & U.S. Mortality 1975-2012, All Races,
Females. Rates are Age-Adjusted).
HPVs are associated with ~60% of oropharyngeal squamous cell carcinomas
(OPSCC) and the number of new cases is predicted to rise [5]. HPV16 is the type most
commonly found in OPSCC and it is responsible for 90% of these cancers [87]. The
increasing rates of HPV-positive OPSCC are most dramatic in developed countries
including the U.S. and incidence is higher in men (Fig 1.5) [82, 88]. As with genital
HPV infections, viral transmission to oral tissues is associated with sexual behaviors [88,
89].
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Figure 1.5 Burden of HPV-positive cancers.
Data highlighting the burden of HPV-associated cancers throughout the world. Cancer type is listed on the
left. Total number of cases for each cancer type is shown in green while those cases attributed to HPV are
shown in red. The number of cancer cases associated with HPV types 16 or 18 are depicted in blue. Data
represent the total number of reported cases worldwide as collected by the EUROGIN 2011 Roadmap [82].

Current treatment of HPV-associated cancers includes surgical intervention as
well as treatment with chemotherapy and radiation.

Multiple targeted therapies,

including EGFR inhibitors, have been attempted for cervical cancer but have shown no
benefit over current standard of care treatments. The EGFR inhibitor, cetuximab, is FDA
approved in conjunction with chemoradiotherapy for the treatment of HNSCC and large
scale clinical trials have reported mixed outcomes in patients with HPV-positive HNSCC
[90].

However, a recent retrospective analysis was conducted of patients with

locoregionally advanced HNSCC receiving radiotherapy with or without cetuximab. In
contrast to previous reports, p16 status and HPV-positivity were correlated with increased
overall survival, progression-free survival and locoregional control [91]. This report
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indicates that further investigation is needed in determining the efficacy of cetuximab and
other EGFR inhibitors in the treatment of HPV-associated cancers.

1.7 HPV Vaccines and Screening
There are currently three FDA approved vaccines against HPV. All three of the vaccines,
Cervarix (GSK), Gardasil-4 and Gardasil-9 (both Merck), offer protection against the
most common high-risk HPV types 16 and 18, which are responsible for 70% of all
cervical malignancies and >90% of HPV-associated HNSCC. Gardasil-4 also includes
HPV types 6 and 11, which cause genital warts. In order to expand the number of
covered HPV types, in 2014, the FDA also approved the first nonavalent vaccine against
HPV. Gardasil-9 provides the same protection as the original quadrivalent Gardasil
vaccine as well as an additional five oncogenic types (types 31, 33, 45, 52, 58).
Although the vaccines are highly effective at preventing HPV infection, there are
still concerns. The largest concern is in regard to vaccine uptake. A complete series of
the vaccine requires 3 doses over a period of one year. The vaccine also requires cold
chain storage, limiting its feasibility in developing countries, which carry the highest
burden of cervical cancer. The cost is also prohibitive with each dose costing ~$130
USD, although the price has been reduced to $5/dose in some developing countries
(American Cancer Society). In order to be effective, the vaccine must be administered
prior to sexual debut causing some concern among parents of adolescents. There are also
limited studies on long-term efficacy of the vaccine [92, 93]. To address some of these
issues, studies are being conducting to determine the efficacy of a partial vaccine series in
inducing a protective immune response.

Several recent reports indicate sufficient
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protection following only one or two doses of the quadrivalent vaccine [94-96].
However, further study is needed to confirm these results. Additionally, to date, none of
the vaccines have shown therapeutic effects in patients already infected with the target
virus types. Therefore, there exists a large patient population who are not able to benefit
from these vaccines. In light of these limitations to the vaccines, development of more
effective treatment options remains critical.
In developed countries, cervical cancer surveillance through Papanicolaou testing
(also known as a Pap smear) has decreased the number of cases of cervical cancer [82].
Routine HPV testing has also been included in the screening protocol. However, in
developing countries, which lack the resources to undertake a screening program of this
nature, cervical cancer remains a significant health burden, where it responsible for 13%
of all cancers in women [82]. Additionally, there are no clinically validated tests to
screen for early detection of HPV-associated HNSCC.

Therefore, the need for

development of more cost effective screening and treatment strategies is apparent.

1.8 The EGFR Pathway
The EGFR pathway appears to be important in multiple stages of HPV infection and
disease progression. Previous studies have shown that EGFR plays an important role in
HPV entry into keratinocytes [97, 98].

Additionally, as outlined earlier, HPV

oncoproteins can upregulate EGFR expression and signaling, indicating this signaling
pathway is significant in the viral lifecycle.
inconsistently in cervical cancer [99].
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Finally, high EGFR has been seen

The epidermal growth factor receptor (EGFR, ErbB1/HER1) is a member of the
ErbB family of transmembrane protein tyrosine kinases. The ErbB protein family is
composed of four members, ErbB1-4, which interact with each other to form homo- or
heterodimers [100, 101]. EGFR contains 3 domains; an extracellular domain that binds
ligand, a hydrophobic transmembrane domain, and an intracellular tyrosine kinase
domain [102]. EGFR is ubiquitously expressed in epithelial cells and performs important
roles in tissue development, growth, and wound healing [103, 104]. Overexpression or
mutation of EGFR is associated with multiple cancer types, including subsets of HPVassociated cancer [99, 105].
Traditional activation of EGFR is initiated by ligand binding to the extracellular
domain [106].

However, ligand-independent activation can also occur via receptor

dimerization in the absence of ligand [107]. Multiple proteins are capable of functioning
as activating ligands for EGFR including its cognate ligand, EGF, as well as TGF-alpha
or amphiregulin (reviewed in [101, 108]). Binding of a ligand to the extracellular portion
of the receptor induces receptor dimerization facilitating transphosphorylation of the Cterminal tail of the receptors [106]. Specific phosphorylation patterns on the intracellular
domain of EGFR are triggered in response to the activating ligand, ligand strength, and
environmental milieu (reviewed in [101]). It is these phosphorylation patterns that are
responsible for directing the intracellular pathway that is to be activated. Following
activation, EGFR is downregulated by endosomal internalization; receptors are then
degraded or recycled back to the plasma membrane [109, 110].
Cellular effects of receptor activation are mediated through downstream signaling
pathways including: PI3K/Akt, Ras/MEK/ERK, JAK/STAT, and phospholipase C [105,

16

111]. Activation of PI3K/Akt and JAK/STAT pathways facilitate cell survival, whereas
the Ras/MEK/ERK and phospholipase C signaling pathways mediate cell proliferation
and survival [112] (Fig 6).

Activation of the Ras/MEK/ERK pathway is mediated

through recruitment of Grb2/Sos by activated EGFR. Which in turn signals downstream
effector proteins in the Ras/MAPK pathway [113].

Figure 1.6 The EGFR signaling pathway.
Upon ligand binding, EGFR dimerizes and transphosphorylation of the C-terminal tail of the receptor
occurs. Signal transduction can proceed through multiple pathways depending on the initiating ligand as
well as environmental factors. Activation of the MEK/ERK signaling pathway occurs through
phosphorylation of Grb2/Sos, which activates Ras. Activation of this pathway results in cell survival and
proliferation. Activation of Akt results in enhanced protein synthesis (activation of mTor) or cell survival
(CREB, NFκB). Signaling through the JAK/STAT pathway also results in cell survival.

The importance of EGFR in cancer development and progression has made it an
attractive target for therapy [114]. To date, multiple small molecule tyrosine kinase
inhibitors and monoclonal antibodies directed at the extracellular domain of EGF have
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been tested in clinical trials and a small number have been FDA approved as targeted
chemotherapeutics [115, 116]. Cetuximab, a humanized monoclonal antibody against
EGFR, was first FDA approved for the treatment of metastatic colorectal cancer with
wild-type KRAS in 2009 and approval has since been granted for metastatic non-small
cell lung cancer and head and neck cancer [117].

Cetuximab works by binding the

extracellular portion of EGFR and inhibiting ligand binding and receptor dimerization
[118]. Binding of cetuximab to EGFR also triggers receptor internalization, effectively
downregulating membrane-associated EGFR levels [119]. There is also thought to be an
immune component in cetuximab’s mechanism of action including activation of
complement and induction of antibody-dependent cellular cytotoxicity (ADCC) [120].

1.9 Importance of EGFR Signaling in HPV-Associated Cancers
HPV oncoproteins are involved in upregulation of EGFR expression and pathway
activation at multiple nodes.

HPV16 immortalization of human keratinocytes was

reported to increase EGFR levels and activation leading to growth factor independence
[121]. EGFR gene expression was also enhanced by E6 and E7 expression in human
keratinocytes retrovirally transduced with the HPV16 genome [122].

Conversely,

inhibition of E6 and E7 in tumor cells reduces EGFR levels as well as cell proliferation
[123].

Additionally, HPV16 E6 activates mTORC1 and MAPK pathways by

upregulation of RTK signaling, including EGFR [124]. As described previously, E5
increases EGFR activation and signaling potential by enhancing receptor recycling back
to the cell membrane after internalization [63-66, 72].
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The EGFR pathway influences expression of the AP-1 family of transcription
factors, which are involved in the regulation of HPV early gene transcription [20, 125,
126]. The AP-1 transcription factor, cFos, which is upregulated upon EGFR activation,
is important in transcription of HPV16 early genes, further indicating that this pathway
plays an important role in the viral lifecycle [127-131]. Also, cells expressing HPV16 E5
have higher levels of c-fos and c-jun transcription factors as well as higher levels of viral
transcription [132].
In cervical cancers, high EGFR expression has been shown in multiple studies.
However, in HNSCCs, high p16 levels, commonly used as a biomarker for HPV, are
inversely correlated with EGFR overexpression [99, 133]. The disparate expression
profiles of EGFR in HPV-associated HNSCC versus cervical cancer are confusing in
light of the aforementioned studies implicating HPV oncoproteins in EGFR upregulation.
However, the majority of the studies investigating the interplay between HPV
oncoproteins and EGFR were performed in overexpression systems utilizing expression
of a single HPV protein and not in the context of viral regulation of gene expression [6367, 72, 122, 123]. Therefore, the extent to which these functions occur in a natural
infection is not known.

1.10 Rationale, Hypothesis, and Goals of This Study
Several reports of the effect of EGFR activation on HPV early transcription have been
published. While it is clear that EGFR activation can modulate HPV transcription, the
studies have not agreed on whether EGFR signaling enhances or inhibits viral gene
expression. Yasumoto, et al. claimed that EGFR activation resulted in downregulation of
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HPV oncogene transcripts E6 and E7, while at the same time enhanced cell proliferation
and c-myc expression [134]. Another group asserted that EGFR activation in SiHa, an
HPV-positive cervical carcinoma cell line, resulted in enhanced E6 and E7 transcript
levels [130]. However, no studies have described the role of EGFR in persistent HPV
infection. In this study, we sought to define the role of EGFR as a mediator of HPV
oncogene transcription in a model of early/persistent infection as well as in a preclinical
model of cancer.
Previous studies implicated HPV oncoproteins in upregulation of EGFR pathway
signaling and highlighted the importance of downstream mediators of EGFR activation,
namely the AP-1 family of transcription factors, in expression of viral oncogenes. Based
on these studies, we hypothesized that upon infection HPV establishes a positive
feedback loop with the EGFR pathway whereupon HPV oncoproteins upregulate EGFR
pathway activity thereby enhancing expression of viral early genes. We furthermore
hypothesized that creating a break in this feedback loop, by inhibition of EGFR or
downstream signaling molecules, would lead to decreased viral activities and restored
levels of p53 tumor suppressor protein.
The goals of the research presented in this dissertation are to (a) determine the
role of EGFR in controlling HPV oncogene transcription in a model of preneoplasia; (b)
define the effect of HPV infection on EGFR signaling in early infection/preneoplasia; and
(c) determine the ability of EGFR inhibitors to inhibit HPV activities in vivo.
The research for this project has been organized into two chapters. In chapter 3, I
address the first two goals in a model of prenoplasia using a cell line maintaining
episomal HPV16 genomes, NIKS-SG3, and its isogenically matched HPV-negative
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parental cell line, NIKS [135].

Chapter 4 reports the data from my in vivo work,

addressing the third goal of this study, using a cohort of four HPV-positive cancer cell
lines propogated to form subcutaneous tumors in the NOD/SCID-gamma xenograft
system.
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CHAPTER 2 - Materials and Methods
2.1 Cell Culture
The NIKS cell line was derived from Normal Immortalized human foreskin
Keratinocytes [136]. The NIKS-SG3 cell line was created by stable transduction of
episomal wild-type HPV16 genomes into NIKS cells, and was a gift from Professor Paul
Lambert (Univ. Wisconsin-Madison) [135]. NIKS and NIKS-SG3 cell lines were cocultured with mitomycin C-treated NIH 3T3 J2 fibroblast feeder cells in E media
containing 10% fetal calf serum (FCS) (Sigma; Atlas Biologicals), with or without
10ng/mL murine EGF (mEGF) (BD Bioscience) as described previously [137].

J2

fibroblasts were cultured in high-glucose DMEM (Irvine Scientific) containing 10%
newborn calf serum, 2mM glutamine (Gibco), 100U penicillin, 1 μg/mL streptomycin
(Sigma), and 5 μg/mL Plasmocin (Invivogen). J2 fibroblasts were treated with 24μM
mitomycin-C (Sigma) for 2 hours followed by washing 3x with at least 5 mL of 1x
phosphate buffered saline (PBS) each. Fibroblast-conditioned E media was obtained
from mitomycin C-treated J2 cells that were incubated 24 h with normal E medium
lacking EGF; media were collected, cell debris removed and media stored at 4°C until
use. For all experiments, keratinocytes were plated without feeder cells in regular E
media or fibroblast-conditioned E media as indicated. SiHa and CaSki HPV16-positive
cervical cancer cell lines were obtained from American Type Culture Collection (ATCC)
and were cultured in Eagle’s Minimum Essential Medium (Corning) or RPMI-1640
(Corning), respectively, supplemented with 10% FCS (Sigma; Atlas Biologicals). UMSCC-47 and UM-SCC-104 HPV16-positive head and neck squamous cell carcinoma
(HNSCC) cell lines were obtained from Prof. Thomas Carey (Univ. of Michigan).
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HNSCC cell lines were cultured in E media containing 10% FCS (Sigma; Atlas
Biologicals). Cell lines not obtained from ATCC were authenticated by short tandem
repeat (STR) analysis (Genetica) and used within 10 passages of verification (Table 2.1).

Table 2.1 Short Tandem Repeat Profiles of Cell Lines

2.2 Flow Cytometry
Keratinocytes were co-cultured with J2-3T3 cells until 1 day prior to assay. J2-3T3 cells
were differentially trypsinized with 1X trypsin/EDTA (Sigma) for 5 minutes. Plates were
washed with 1X PBS and keratinocytes were dissociated from the plate using 0.25%
trypsin/EDTA (Sigma). Cells were plated at subconfluent density and allowed to attach
overnight. Subconfluent cells were washed with 1x PBS and incubated with 0.25%
trypsin/EDTA (Sigma) for 20 minutes. Trypsin was quenched with an equal volume of
media containing 10% FCS. Cells were pelleted at 1K RPM for 5 minutes and
resuspended in 1X PBS, 2 μg of Alexa-fluor 647 labeled anti-EGFR antibody (clone R-1,
Santa Cruz) was added and cells incubated at 4°C for 30 minutes to allow antibody
binding. Labeling of microspheres was carried out alongside cells for each experiment.
Cells and microspheres were held on ice following labeling. Cells and microspheres
were pelleted and washed with cold 1x PBS. Following washes, cells and microspheres
were resuspended in cold 1x PBS and held on ice. Cells and microspheres were analyzed
on LSRFortessa flow cytometer (Becton Dickinson). Microspheres were gated on most
populated area, cells were gated on live singlets. Unlabeled cells and microspheres were
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run as controls on every run. Median fluorescence intensity was taken for each sample at
using the full width of the peak at mid-height. Regression curves were created using
QuickCal v2.3 Data Analysis Program (Bangs Laboratories) and antibody binding
capacity for cells was determined from that experiment’s standard curve. Experiments
with a r2 of <0.95 were not used. Average of r2 for the experiments was 0.98. Data were
reported as the number of antibodies bound per cell. Anti-EGFR clone R-1 is a
monoclonal antibody which binds EGFR at a 1:1 ratio, therefore data can be expressed as
the number of receptors per cell. Data shown are the result of at least 3 independent
experiments.
2.3 Nucleic Acid Extraction
Cells were collected in TriReagent (Sigma) at 500 µL/well of 12-well plate. Plates were
incubated at room temperature for 5 minutes and cell lysates transferred to Eppendorf
tubes. Samples were stored at -20°C until extraction. RNA and DNA extraction were
carried out according to manufacturer’s protocol. RNA was DNase treated and yield
determined as outlined in section 2.5.
2.4 RNA Extraction from Xenografts
Total RNAs were extracted from frozen tumors using Direct-zol RNA MiniPrep kit
(Zymo) according to manufacturer’s protocol. Briefly, frozen tissues were weighed,
thawed in TriReagent (at least 1ml Trizol per 100mg tissue) (Sigma) and homogenized
using a Pro200 rotory homogenizer (Pro Scientific). Lysates were held at 4°C overnight.
Non-soluble material was removed by centrifugation (12K x g for 10 minutes) at 4°C and
supernatant was transferred to a fresh tube. An equal volume of 100% ethanol was added
to supernatant to precipitate nucleic acids. Solution was applied to Zymo column and
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washed. Following wash steps, RNA was eluted in RNase-free dH2O. DNAse treatment
was carried out as outlined in following section.
2.5 DNase Treatment of RNA
To remove contaminating DNA from RNA, samples were DNase treated using Turbo
DNA free kit (Ambion) according to the manufacturer’s directions. RNA concentration
and purity was determined by spectrometry (Nanodrop, ThermoScientific). Quality and
concentration of RNA was determined by spectrometry (Nanodrop, BioRad) and agarose
gel electrophoresis as described in [138].
2.6 RT-qPCR
Reverse transcription of total RNAs was carried out at 42°C for 60 minutes using MMLV reverse transcriptase and random primers (Applied Biosystems). 25ng of template
(10ng for UM-SCC47, 5mg/kg cetuximab cohort) was used for each qPCR reaction.
Sequences of primer/probes and cycling conditions are provided in Table 2.2. iQ Master
mix (BioRad) was used for hydrolysis probes, JunB primers were obtained from Applied
Biosystems and used with TaqMan Advances Master mix (Applied Biosystems), all othe
reactions used SsoFast Evagreen Master mix (BioRad) All qPCR reactions were run on
CFX96 thermocycler (BioRad) and data analyzed using BioRad CFX Manager (version
3.1.1517.0823). Cq values for targets were normalized to human B-actin expression
levels using the ΔCq method.
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Table 2.2 Primer Sequences and qPCR Cycle Conditions

2.7 Immunoblotting
Cells were washed in cold 1X PBS and lysed on ice for 5 minutes with cold 1X
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1%
Triton-X 100, 0.1% sodium dodecyl sulfate, 5mM EDTA, 1% deoxycholic acid)
supplemented with 1X HALT protease inhibitors (Thermo Scientific) and 0.2 mM
activated sodium orthovanadate. Lysates were transferred to an Eppendorf tube and
centrifuged at 12K x g for 15 minutes at 4°C. Supernatant containing soluble protein was
transferred to a fresh tube and protein concentration determined by Bradford Assay
(BioRad). 6X Sample Loading Buffer (0.35 M Tris-Cl pH 6.8, 0.347 M SDS, 0.602 M
dithiothreitol, 40% glycerol, 0.5% bromophenol blue) was added to a final concentration
of 1X, samples were boiled for 10 minutes and stored at -20°C.
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Proteins were separated on SDS-PAGE gel (TGX, BioRad) and transferred to
PVDF or nitrocellulose membranes. See Table 2.3 for antibody specific blocking and
incubation information.

Following transfer, membranes were incubated in blocking

buffer at room temperature for 1 hour. Primary antibody diluted in blocking buffer was
added and incubated overnight. Secondary HRP-conjugated anti-mouse or anti-rabbit
antibody (GE) diluted 1:10K in blocking buffer was added and membrane incubated at
room temperature for 1 hour.

When required, membranes were stripped (Western

stripping buffer, pH 2.5 - 0.05% Tween-20, 0.2M glycine in 1X PBS) and reblocked prior
to reprobing. Membranes or exposed films were scanned using a ChemiDoc (BioRad)
and densitometry preformed using Bio-Rad Image Lab software (version 2.0).

Table 2.3 Antibodies and Conditions Used for Immunoblotting!

2.8 Xenograft Preparation
To establish xenografts, cells (1–2 x 106 mixed 1:1 with Matrigel (BD Biosciences) were
injected subcutaneously into flanks of 8-10 week old, female NOD/SCID-gamma (NSG)
mice. Once tumors were palpable, they were measured by caliper, stratified by size, and
animals randomized into treatment and control groups. Cetuximab (0.5, 1, or 5 mg/kg) or
0.9% saline control was administered 3x/week by i.p. injection. Trametinib (1 mg/kg) or
vehicle control (10% Cremophor EL, 10% PEG 400) was administered daily by oral
gavage. Tumors were measured by caliper 3x/week and volumes calculated using the
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formula: length x width x width/2. Xenografts were harvested when the control group
reached 1 cm in size. Tumors were surgically removed, divided for histology, RNA, and
protein extraction.

Tumor sections were snap frozen in liquid nitrogen, histology

portions were embedded in OCT and snap frozen except UM-SCC47/cetuximab 5mg/ml
and UM-SCC104 which were fixed in 10% formalin overnight then transferred to 100%
ethanol until processed. Frozen tumor sections were stored at -80°C until use. The
Institutional Animal Care and Use Committee of the University of New Mexico Health
Sciences Center (Albuquerque, NM) approved all animal procedures (UNM HSC
Protocol # 100924).
2.9 Immunohistochemistry
Formalin-fixed paraffin embedded (FFPE) blocks were sectioned at 5 μm thickness and
transferred to charged slides (Fisher Scientific). Sections were deparaffinized in Citrisolv
(Fisher Scientific) and rehydrated through 70% ethanol followed by 10 minutes in dH2O
(for H&E) or 1X PBS (for IHC). For manually stained IHC slides, antigen retrieval was
performed by boiling slides in appropriate buffer for indicated times (see Table 2).
Blocking was performed in 5% normal horse serum (Vector Labs), 1 hour at room
temperature. The following antibodies were used for IHC: total-EGFR (Cell Signaling),
phospho-EGFR(Y1173) (Cell Signaling), phosphor-p44/42 (Cell Signaling), Ki-67 (BD
Biosciences/Thermo Scientific), p16INK4a (Roche/Ventana, performed by UNM Human
Tissue Repository), p53-D07 (Novocastra, performed by MD Anderson Research Park
Histology Core), human mitochondria marker (Chemicon, done by MD Anderson
Research Park Histology Core). Manually stained sections were incubated with primary
antibody in blocking solution overnight at 4°C in a humidified chamber (see Table 2 for
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antibody concentrations). Slides were washed in TBS-T, and incubated with biotinylated
anti-mouse/rabbit secondary antibody (VECTASTAIN Elite Universal ABC Kit, Vector
Labs) for 30 minutes followed by 30 minutes incubation with ABC reagent. Sections
were incubated with DAB (Vector Labs) for 15 minutes. Slides were counter stained
with hematoxylin, dehydrated and cleared in Citrisolv. Coverslips were mounted with
Permount mounting media.

Table 2.4 Antibodies and Conditions Used for Immunohistochemistry

2.10 Histological Evaluation
Blinded tumor sections were evaluated and all HALO analysis was perfromed by a
certified pathologist (Dr. Donna Kusewitt of the UNM Comprehensive Cancer Center).
IHC stained tissues were assigned a score between 0-3 based on epithelial staining
intensity with 0 representing the lowest intensity and 3 representing the strongest. For
evaluation of tissue morphology, Aperio-scanned H&E-stained slides and the HALO
(Indica Labs) morphometry system were used. The entire tumor mass was outlined to
obtain the total tumor area. HALO was then trained to recognize viable tumor epithelium,
keratin, stroma, large blood vessels, and background (no tissue) within the tumor.
Necrotic areas within the tumor epithelium were outlined by hand for exclusion in
calculations. HALO was reprogramed for each cell line because of vastly different
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morphologies. HALO determined the area of these components and percentage of the
entire tumor occupied by these areas was calculated by the pathologist. Areas of tumor
epithelium were confirmed by IHC for human mitochondrial marker. Ki67 IHC slides
were also scanned into Aperio and analyzed using HALO. HALO was trained to
recognize epithelium and then to identify Ki67-positive nuclei in that epithelium. Positive
nuclei were classified as strongly (+3), moderately (+2), or weakly (+1) positive
(considered background). The number of strongly and moderately positive nuclei (+2,
+3) were normalized to the area of the epithelium.
2.11 RNAscope® - RNA ISH
FFPE sections were stained according to manufacturer’s protocol (2.5 HD Detection Kit
– Brown) using a probe to high-risk HPV E6/E7 (hrHPV 7, Advanced Cell Diagnostics).
Briefly, fresh cut sections were deparaffinized in xylenes (2 x 5 minutes each) and
washed in 100% ethanol (2 x 1 minutes each). Exogenous peroxidase was quenched by
incubation with 3% H2O2 (Advanced Cell Diagnostics) for 15 minutes then washed with
dH2O. Slides were submerged in sub-boiling temp Antigen Retrieval Buffer (Advanced
Cell Diagnostics) for 15 minutes followed by washing in dH2O then 100% ethanol.
Tissues were encircled with a hydrophobic pen and slides were allowed to dry overnight.
Slides were incubated in protease (Advanced Cell Diagnostics) 30 minutes, 40°C then
washed in dH2O. High risk HPV E6/E7 probe was hybridized for 2 hours at 40°C. AMP
steps 1- 4 were performed for recommended lengths of time at 40°C, with 2 minute
washes in 1x Wash Buffer (Advanced Cell Diagnostics) between each amplification step.
The final two AMP steps (5 and 6) were performed at ambient temperature for
recommended times, slides were washed with 1x Wash Buffer after each step. Signal
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detection was performed with DAB (Advanced Cell Diagnostics) for 10 minutes at
ambient temperature. Tissues were counterstained with 50% Gil’s hematoxylin solution,
coverslipped and allowed to dry overnight. Slides were digitally scanned (Aperio Slide
Scanner) and analyzed using HALO software by Dr. Kusewitt.
2.12 Statistical Analysis
All statistics for growth curves and RT-qPCR experiments were performed in GraphPad
Prism version 6.0g for Mac. Statistical analysis for in vitro experiments was performed
using the Student’s t-test or 2-way ANOVA.
compared by multiple t-tests (unpaired).

Growth curves for xenografts were

RT-qPCR data was compared by t-test.

Correlation between tumor size and transcript expression levels was determined by
Spearman’s r test. Statistical outliers were determined for each experimental group using
Grubb’s outlier test. Semi-quantitative histology results were compared using MannWhitney. Error bars represent the standard error of the mean (SEM) for each group. Pvalues of less than 0.05 were considered to be significant.
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CHAPTER 3 - Inhibitors of the EGFR and MEK signaling pathways have antiviral
activities in HPV16-infected keratinocytes
Abstract
Human papillomaviruses (HPVs) are the most common sexually transmitted infectious
agents.

A subset of HPVs are oncogenic and can initiate cancers of the mucosal

epithelium.

HPVs are involved in >99% of all cervical cancers, as well as other

anogenital cancers.

An increasing percentage of oropharyngeal cancers are also

associated with HPV16 infection. Previous studies suggest there is interplay between the
EGFR pathway and oncogenic HPV activities including the ability of viral oncoproteins
to augment EGFR signaling and EGFR effectors to influence HPV gene expression. We
therefore hypothesize that, upon infection, the oncogenic HPVs establish a positive
feedback loop with the EGFR pathway wherein viral oncoproteins enhance host cell
signaling, which in turn results in upregulation of early viral gene transcription. We
further postulate that interruption of this loop would lead to decreased viral oncoprotein
levels and sensitize the cells to apoptotic stimuli. To test these hypotheses we used
syngeneic HPV-negative and HPV16-positive cell lines, the latter harboring episomal
viral genomes and modeling early HPV infection. We found that EGFR stimulation
upregulated viral early transcription whereas treatment with cetuximab, an EGFR
inhibitor, resulted in decreased viral transcript levels, as hypothesized. Furthermore, in
the cell line harboring episomal HPV16 genomes, sustained EGFR inhibition led to
reduced viral genome levels. Our results demonstrate that EGFR inhibitors display
antiviral activity including reduction of viral oncogene expression and diminished
episomal viral genome burden. These data suggest that EGFR inhibitors should be
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investigated clinically for their anti-HPV effects, which may reduce tumor growth and/or
be useful as neoadjuvants to sensitize HPV-induced tumors to effective doses of DNA
damaging agents.
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3.1 Introduction
Human papillomaviruses (HPVs) are the most prevalent cause of sexually transmitted
infections and the majority of sexually active individuals will become HPV infected in
their lifetime [81]. There are over 100 genotypes of HPVs that are grouped into high- and
low-risk types based on their ability to cause lesions with a high-risk of progressing to
malignancies [10]. The oncogenic HPVs are estimated to be responsible for nearly 5% of
all cancers worldwide [5]. The role of oncogenic HPVs, including HPV types 16, 18 and
31, in the development of cervical cancers is well-documented [139]. Additionally,
HPVs are implicated as etiological agents of cancers at other anogenital sites, as well as a
subset of cancers of the oropharynx [5-7].
The HPV oncogenes E5, E6 and E7 are required for a productive viral infection.
These proteins are expressed early in the viral life cycle and enhance cellular
proliferation and survival, enabling a productive viral lifecycle ending in production of
viral progeny [140]. The best-known functions of E6 and E7 are inactivation of key cell
cycle checkpoint and tumor suppressor proteins, p53 and pRb, respectively. E6 degrades
p53 via the ubiquitin ligase pathway, whereas E7 destabilizes and inactivates pRb [43,
44, 58, 141, 142]. The E5 protein augments epidermal growth factor receptor signaling
and enhances transformation by E6 and E7 [143]. However, the functions important in
the productive life cycle can become dysregulated and lead to transformation. E6 and E7
can each induce cellular immortalization [39-42]. In a productive infection, the viral E2
protein negatively regulates E6 and E7 expression, thus striking a balance between host
cell proliferation and the need for increased epithelial differentiation to complete the later
stages of the HPV life cycle [144].
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The EGFR signaling pathway appears to be vital in HPV infections both during
entry and establishment of infection as well as the maintenance of a persistent infection.
EGFR is a crucial regulator of many epithelial processes and mediates responses to
various external stimuli [110]. Normally, activation of EGFR occurs by binding of
ligand to the extracellular portion of the receptor, followed by receptor dimerization,
trans-phosphorylation and activation of downstream signaling molecules. EGFR signal
transduction leads to cellular proliferation, migration and/or survival and is important in
tissue development, growth and wound-healing responses [108, 110].
We previously showed that EGFR activation plays an essential role in the initial
infection of human keratinocytes by oncogenic HPVs, perhaps by regulating virus uptake
into cells [98, 145, 146]. EGFR also appears to be important following establishment of
infection. Many prior studies reported that HPV proteins, typically when ectopically
over-expressed in isolation or in transformed cells, augment EGFR signaling and provide
a cellular growth advantage. For instance, E6 and E7 each upregulates EGFR expression
at the genome level [122, 123]. E5 increases EGFR recycling to the cell surface after
activation-induced internalization, possibly through E5’s viroporin-like activities in the
early endosome [63-67, 72].

In addition to providing a cellular phenotype that is

favorable to the HPV life cycle, EGFR signaling may play a more direct role in the
establishment and maintenance of a productive infection.

The long control regions

(LCR) of oncogenic HPV genomes contain multiple binding sites for many transcription
factors including AP-1 transcription factors, which are downstream effectors of EGFR
signaling (reviewed in [125]). AP-1 family members have been shown to mediate early
transcription of HPV16 [127-131] and HPV18 [147, 148 Zenz, 2005 #3596, 149].
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The data showing that HPV16 oncoproteins can increase EGFR signaling and that
EGFR’s downstream effectors can upregulate HPV early transcription led us to
hypothesize that oncogenic HPV infection establishes a positive feedback loop with the
EGFR signaling pathway (Fig 3.1A). We posit that HPV mediated upregulation of
EGFR signaling in infected cells promotes increased transcription of viral oncogenes and
contributes to the maintenance of infection. The corollary to this hypothesis is that
creating a break in this pathway, through inhibition of EGFR, would downregulate viral
oncogene transcription and allow recovery of functional p53 facilitating sensitization of
cells to apoptotic stimuli (Fig 3.1B).
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Figure 3. 1 Hypothesized feedback loop between HPV and EGFR.
HPV enhances EGFR expression and signaling, resulting in upregulation of viral oncogene expression (A).
We hypothesize that creating a break in the feedback loop via use of EGFR pathway inhibitors is
hypothesized to downreguate viral oncogene expression and protein levels and allow recovery of functional
p53 and pRb (B).
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3.2 Methods
3.2.1 Cell Culture
The NIKS cell line was derived from normal immortalized human foreskin keratinocytes
[136]. The NIKS-SG3 cell line was created by stable transduction of an episomally
replicating, circular wild-type HPV16 genome into NIKS cells and was a gift from Prof.
Paul Lambert (Univ. Wisconsin-Madison) [135]. NIKS and NIKS-SG3 cell lines were
co-cultured with mitomycin C-treated NIH 3T3 J2 fibroblast feeder cells in E media
containing 10% fetal calf serum (FCS) (Sigma; Atlas Biologicals), with or without 10
ng/mL murine EGF (mEGF) (BD Bioscience) as described previously [137].

J2

fibroblasts were propagated in high-glucose DMEM (Irvine Scientific) supplemented
with 10% newborn calf serum (Atlas Biologicals), 2mM glutamine, 100U penicillin, 1
ug/mL streptomycin (Sigma), and 5 ug/mL Plasmocin (Invivogen). J2 fibroblasts were
treated with mitomycin C (24uM) for 2 hours followed by washing 3x with at least 5 mL
of 1X phosphate buffered saline (PBS) each. Cell lines were authenticated by short
tandem repeat analysis (Genetica) and used within 10 passages of verification.
Fibroblast-conditioned E media was obtained from mitomycin C-treated J2 cells that
were incubated 24 h with normal E medium lacking EGF; media were collected, cell
debris removed and media stored at 4°C until use. For all experiments, keratinocytes
were plated without feeder cells in regular E media or fibroblast-conditioned E media as
indicated.
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3.2.2 Cell Viability Assays
Cells were treated for 7 days in fibroblast-conditioned E medium lacking exogenous
EGF; media were replaced every 48 hours. MTT assays were performed according to the
manufacturer’s directions (Invivogen).
3.2.3 Treatment With Targeted Inhibitors
Cetuximab (2 mg/mL, Bristol-Myers Squibb) was obtained from the University of New
Mexico Hospital Pharmacy.

Stock solutions of PD98059 (Sigma), BKM120, and

SB202190 (both Selleck Biochemicals) were prepared in DMSO at 50 mM, 1 mM, and
50 mM respectively. Experimental samples were normalized to vehicle-only treated cells
containing an equal concentration of 0.9% NaCl (cetuximab and EGF) or DMSO
(tyrosine kinase inhibitors).
3.2.4 Cisplatin Treatment
To evaluate changes in levels of p53 induction in EGF and EGFR inhibitor treated cells,
DNA damage was initiated by addition of 6.6uM (IC30 as determined by MTT assay)
cisplatin (Sigma) to cell culture media. Where indicated, cells were treated with cisplatin
for 24 hours prior to protein harvest.
3.2.5 Protein Isolation and Immunoblot
Subconfluent plates of cells were lysed on ice in RIPA buffer (50mM Tris, 150mM NaCl,
1% Triton X-100, 0.1% SDS, 5mM EDTA, 1% deoxycholic acid) supplemented with 1X
HALT protease/phosphatase inhibitor (Pierce), and 0.2mM sodium orthovanidate.
Samples were centrifuged at 12K x g for 15 minutes at 4°C and supernatants transferred
to new tubes.

Protein concentrations were determined by Bradford assay (BioRad
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Protein Reagent). Laemmli sample loading buffer (6X) (62.5 mM Tris-HCl pH 6.8, 2%
sodium dodecyl sulfate, 40% glycerol, 0.05% bromophenol blue) with 0.05% βmercaptoethanol was added to samples to a final concentration of 1%. Total proteins
(10-20µg) were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. Proteins were transferred to Immobilon-P PVDF membrane (Millipore)
using the TransBlot Turbo semi-dry transfer system (BioRad) or wet transfer using
western transfer buffer (0.25 M Tris, 0.192 M glycine, 20% methanol). Membranes were
blocked with 1% bovine serum albumin in Tris buffered saline-Tween-20 (20 mM Tris,
137 mM NaCl, 0.1% Tween-20) (TBS-T) and incubated with primary antibodies
overnight at 4°C. Antibodies from Cell Signaling: p-EGFR (Tyr1173) (53A5) and pEGFR (Tyr1068) (D7A5), p-p44/42 MAPK (20G11), total EGFR (D83B1) (each 1:1000
overnight at 4°C). Antibodies from Calbiochem: p53 (DO-1) (1:1000), p16 (NA29)
(1:200). HRP-conjugated anti-mouse and anti-rabbit secondary antibodies (Abcam and
Millipore) were used at a 1:10,000 dilution. Separate blots were prepared for phospho
and total proteins.

Membranes were stripped using mild PVDF stripping buffer

(399.6uM glycine, 3.5uM SDS, 1% Tween 20, pH 2.2) for 10 min at room temperature
followed by extensive washing in TBST. Stripped blots were re-blocked as described
above then re-probed for β-actin as a loading control. Blots were visualized on a BioRad ChemiDoc station and analyzed by densitometry using Bio-Rad Image Lab software
(version 2.0).
3.2.6 Nucleic Acid Collection and Analysis
Cells were lysed in TriReagent (Sigma) and RNA and DNA extracted per the
manufacturer’s directions. RNA was DNase treated using the TURBO DNA-free kit
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(Ambion). Reverse transcription of total RNAs (0.5-1 ug each) was performed at 42°C
for 60 minutes. Quantitative polymerase chain reaction (qPCR) was used to quantify
HPV16 transcript (cDNA) levels as previously reported [137]. The HPV16 transcripts
targeted included E6 and E7 (Bio-Rad SsoFast EvaGreen Supermix) and E1^E4/E5 (BioRad iQ Supermix); viral cDNA levels were normalized to cellular β-actin cDNA levels
(Bio-Rad iQ Supermix). Total DNA (0.5ug) was used for qPCR analysis of viral genome
copy numbers using primers targeted to the HPV16 long control region (LCR) (Bio-Rad
SsoFast EvaGreen Supermix). qPCR reactions were performed on a Bio-Rad CFX96 and
analyzed using Bio-Rad CFX Manager (version1.6.541.1068).

All qPCR data were

normalized to reference levels using the ΔCq method [Ratio (reference/target)=2Cq(reference)C (target)
q

] and expressed as percent or fold change relative to mock or untreated sample.

Statistical analysis was performed using the Student’s t-test or 2-way ANOVA in
GraphPad Prism statistical software (Version 6).
3.2.7 Measurement of Cell Surface EGFR
Keratinocytes were seeded at 1x106 cells/well of a 6-well plate without fibroblast feeder
cells in complete E media lacking EGF and allowed to attach overnight. Cells were
dissociated using 0.25% trypsin-EDTA (Sigma) for 20 minutes. Trypsin was quenched
with complete E medium and cells pelleted at 1K RPM for 5 minutes followed by
washing with 2 mL cold 1X PBS. Cells were resuspended in 100 µL of cold 1X PBS and
incubated with 2 µg AlexaFluor-647 labeled anti-EGFR antibody R-1 (Santa Cruz
Biotechnology) for 30 minutes at 4°C with mixing.

Antibody-binding beads from

Quantum Simply Cellular anti-Mouse Kit (Bangs Laboratories) were labeled
concurrently for each experiment. Cells and beads were each washed and resuspended
41

according to manufacturer’s directions.

Fluorescence signal was detected by flow

cytometry using BD LSR Fortessa (Flow Cytometry Shared Resource Center supported
by the University of New Mexico Health Sciences Center and the University of New
Mexico Comprehensive Cancer Center) and data were analyzed using FACS DIVA
software. Regression curves were created using median fluorescence from each bead
population with the QuickCal v2.3 Data Analysis Program (Bangs Laboratories).
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3.3 Results
3.3.1 EGF Stimulation Results in Increased Viral Transcription in HPV16-Positive
Human Keratinocytes
Previous studies indicated that EGFR signaling can modulate HPV early transcription.
For example, EGF stimulation of SiHa cells, a cervical cancer cell line harboring
integrated HPV16 genomes, resulted in increased E6 and E7 gene expression [130].
However, EGFR activation in other keratinocyte cell lines immortalized with HPV16 and
harboring integrated viral genomes inhibited HPV early transcription [134]. NIKS-SG3
is an HPV16-positive cell line developed from the near diploid NIKS human keratinocyte
cell line, and maintains ≈1-10 copies per cell of extrachromosomal HPV16 genomes.
These cells initiate late virus life cycle stages when cultured as differentiating
organotypic tissues [135], thus representing a persistently HPV16-infected, pre-neoplastic
state. To determine how EGF stimulation affects viral transcription in the proliferative
context of episomally replicating HPV16 genomes, NIKS-SG3 cells were cultured in the
presence of a physiologically relevant level of EGF (5 ng/mL). HPV16 early transcripts
potentially encoding the oncoproteins E6, E7, and E5 were quantified to reveal increased
viral transcript levels at 24 h, and significantly higher levels by 48 h post treatment (Fig
3.2). These data indicate EGF activation and likely EGFR signaling has a positive effect
on HPV transcription in proliferating cells maintaining episomal HPV genomes.

43

Figure 3.2 EGF stimulation results in increased viral transcription in HPV16-positive NIKS-SG3
cells.
Cells were incubated in the presence of 5 ng/mL EGF for the indicated times. Total RNA was analyzed by
RT-qPCR for levels of HPV early transcripts E6 (A), E7 (B) or E1^E4/E5 (C). Results were normalized to
β-actin transcripts and are shown as fold-change over mock treated cells. Error bars = SEM, *p<0.05,
***p<0.001. Data summarizes 4 independent experiments.

3.3.2 HPV16 Infection Does Not Significantly Alter EGFR Expression or Signaling
in Proliferating Cells
HPV infection is well documented to render cells less dependent upon EGF for
proliferation or survival [132, 135, 150]. HPV early proteins E5, E6 and E7 have each
been reported to enhance EGFR expression and/or downstream signaling in cells
ectopically expressing high levels of these proteins [63-66, 72, 122]. However, whether
the viral oncoproteins expressed from their natural promoters and in the physiologically
relevant context of replicating HPV16 genomes can modulate EGFR signaling in
proliferating human keratinocytes has not been investigated to our knowledge. We
therefore sought to determine if HPV status conferred any differences in EGFR
expression or signaling in isogenically matched NIKS cell lines.
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Figure 3.3 Cells maintaining HPV16 genomes do not exhibit significantly heightened EGFR
signaling, and remain sensitive to EGFR pathway inhibition.
(A) The number of EGFR proteins on plasma membrane was quantified by flow cytometry. An average of
three independent experiments is shown. (B) NIKS and NIKS-SG3 were serum-starved for 8h and treated
with 100 µg/mL cetuximab or 25µM PD98059 before (4 hours/cetuximab or 1 hour/PD98059) and during
exposure to 10 ng/ml EGF in serum-free media for 5 minutes. The results of three independent
experiments are quantified in (C). M = media only, E = EGF only without inhibitor, C=Cetuximab,
P=PD98059. Error bars = SEM.

Quantitative comparison of cell surface EGFR levels between the parental NIKS and
NIKS-SG3 cells revealed slight, but not significantly lower, EGFR levels on the HPV16
positive NIKS cells (Figure 3.3A).

A previous study noted that human foreskin

keratinocytes (HFKs) transduced with a retroviral vector expressing HPV16 E6 had
hyper-activated EGFR signaling in a ligand-dependent manner and sustained receptor
activation in the absence of ligand [124]. We thus strove to determine whether the NIKS
cells persistently infected with HPV16 acquired increased EGFR activity independent of
receptor levels. EGFR contains multiple phosphorylation sites that direct downstream
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signaling pathways and we chose to target phosphorylation at tyrosine residues 1173 and
1068 (Y1173 and Y1068, respectively), which are both capable of activating the
Grb2/Sos signaling cascade that includes Ras/MAPK/MEK [151, 152]. Subconfluent,
serum-starved NIKS and NIKS-SG3 cell lines were subjected to EGF stimulation. We
observed heightened EGFR and downstream activation in some experimental replicates,
measured by phospho-EGFR (Y1068 and Y1173) and phospho-44/42 (MEK1/2), in
NIKS-SG3 cells as compared to parental HPV-negative NIKS cells upon ligand-induced
activation (Fig 3.3B, lanes 2 and 5). However, no statistically significant differences were
observed when replicates were averaged from multiple independent experiments (Fig
3.3C). These data suggest that HPV16 early gene expression may increase signaling
downstream of EGFR, but this is not pronounced in proliferating cells.

3.3.3 HPV16-Positive Cells Are Sensitive to EGFR and MEK Inhibitors
To test the sensitivity of the cell lines to EGFR and MEK pathway inhibitors, we
pretreated cells with the EGFR antagonist cetuximab, a monoclonal antibody that blocks
ligand activation and induces receptor downregulation [153], or PD98059, a potent
inhibitor of MEK1/2, prior to stimulation with EGF. Cetuximab inhibited EGF-mediated
EGFR activation in both HPV-negative and HPV-positive cell lines as measured by
detection of p-EGFR (Y1068) (Fig 3.3B lanes 3 and 6) and p-EGFR(Y1173) (data not
shown), and completely diminished p-44/42 (MEK1/2) levels in the cell lines (Fig 3.3B
lanes 3 and 6). Furthermore, treatment with PD98059 resulted in complete block of
ERK1/2 phosphorylation in both cell lines (Fig 3.3B lanes 4 and 8). Therefore, HPV
infection does not markedly alter sensitivity of NIKS-SG3 to EGFR/MEK inhibitors.
46

3.3.4 EGFR Signaling Dependency in HPV16-Positive Cells
Previous studies found that HPV16 early gene expression, in particular the E5 gene
product, provides cells with growth factor independence [132, 135, 150]. Therefore, we
expected the NIKS cells maintaining episomal HPV16 genomes would have a survival
advantage compared to their uninfected parental NIKS cells when EGFR signaling was
inhibited. The cell lines seeded at subconfluent densities were treated with increasing
concentrations of inhibitors or vehicle for 7 days. Treatment media were refreshed every
2 days and cell viability was determined on day 7.

Figure 3.4 Dependence of HPV-positive and HPV-negative NIKS on EGFR and MEK1/2 signaling
for cell survival.
NIKS and NIKS-SG3 cells were grown 7 days in the presence of cetuximab (10 µg/mL, 100 µg/mL, 1
mg/mL) (A) or PD98059 (2.5 µM, 25 µM, and 250 µM) (B). Data are the result of 3 independent
experiments. Error bars = SEM. *p<0.05.
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At the highest concentrations tested (1.0 mg/ml cetuximab), the HPV-negative and HPVinfected NIKS cells had similar viability (Fig. 3.4A). However, the NIKS-SG3 cells were
less sensitive to the EGFR inhibitor at the lower concentrations tested (Fig. 3.4A).
Viability in the presence of MEK1/2 inhibition was also evaluated. NIKS-SG3 cells
exhibited significantly higher viability in the presence of low dose (2.5μM PD98059)
MEK inhibitor than HPV-negative NIKS (Fig. 3.4B). There was no apparent difference
in viability at moderate dosage of inhibitor which reduced NIKS viability to similar
levels as the 0.1 mg/mL cetuximab treatment. However, we found that NIKS-SG3 cells
were much more sensitive to higher doses of MEK1/2 inhibition than NIKS, and this was
true across multiple independent experiments (Fig. 3.4B). These findings indicate the
EGFR/MEK pathway is important for the proliferation of human keratinocytes whether
they maintain HPV genomes or not, but show that HPV16 infection significantly reduces
the dependence of the cells on EGFR and MEK1/2 signaling. This data supports our
hypothesis that HPV affects the EGFR pathway and agrees with previous studies
indicating that HPV infection partially imparts growth factor independence to infected
cells [132, 135, 150].

3.3.5 EGFR/MEK Inhibition Has Antiviral Effects
As EGFR pathway activation resulted in increased HPV transcription in cells maintaining
episomal viral genomes (Fig. 3.2), we predicted that inhibiting EGFR signaling would
have a negative effect on viral activities. Cells were grown in the presence of 100 μg/mL
cetuximab, the intermediate concentration tested in Fig 3.4A, and total early viral
transcript levels were assessed (Fig 3.5A).
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EGFR inhibition resulted in a marked

decrease in HPV16 E6, E7 and E1^E4/E5 transcript levels by 24 h treatment. Inhibition
of the MEK1/2 signaling pathway by PD98059 produced similar downregulation of early
viral transcripts (Fig. 3.5B). However, inhibition of PI3K, which is often mutated in in
HPV-positive cancers, with BKM120 did not alter expression levels of viral early
transcripts (Fig. 3.5C) [154].

Figure 3.5 Inhibition of EGFR signaling decreases viral early transcript levels in NIKS cells
maintaining episomal HPV16 genomes.
NIKS-SG3 cells were treated with 100 µg/ml cetuximab, 25 µM PD98059, or 0.5 or 0.05μM BKM120.
mRNA was harvested at indicated time points and RT-qPCR performed for HPV early transcripts for
cetuximab (A), PD98059 (B), or BKM120 treated cells (48 hours treatment) (C). Data were normalized to
β-actin transcript levels. Mock = vehicle only. Data analyzed by 2-way ANOVA (multiple comparisons).
Error bars = SEM, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Graphed are the results of 2
independent experiments performed in duplicate.

As early HPV gene expression is needed for viral genome maintenance (reviewed
in [18] and [17]), we surmised viral DNA replication might also be negatively impacted
by reduced EGFR/MEK signaling. We detected a statistically significant decrease in
viral genome copies by 48 hours post-exposure to either inhibitor, and levels continued to
diminish over six days of treatment (Fig 6). Together, these data indicate that cetuximab
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has anti-viral effects in cells harboring episomal HPV genomes. MEK inhibition resulted
in almost identical decrease of viral transcription and genome levels while PI3K
inhibition had no effect on viral transcript levels. These data indicate that EGFR signal
transduction through the MEK/ERK pathway is responsible for mediating the viral
effects, and further support our hypothesis that EGFR signaling modulates HPV16 early
transcription.

Figure 3.6 Inhibition of EGFR and MEK signaling decreases viral genome copy numbers in NIKS
cells maintaining episomal HPV16 genomes.
NIKS-SG3 cells were treated with 100 µg/ml cetuximab or 25 µM PD98059. Total cellular DNA was
harvested at indicated time points and qPCR performed for HPV16 LCR. Data were normalized to total µg
DNA. Mock = vehicle only. Data analyzed by 2-way ANOVA (multiple comparisons). Error bars = SEM,
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Graphed are the results of 2 independent experiments
performed in duplicate.

3.3.6 HPV-Infection Does Not Significantly Alter p53 Levels in NIKS-SG3
We showed HPV16 early gene expression is responsive to activation or inhibition of
EGFR signaling. Thus, we expected the levels of viral oncoproteins and oncoprotein
activities to coincide with altered EGFR signaling. Specifically, we anticipated changes
in E6/E7 RNA and protein to inversely correlate with p53 levels. E6 and E7 protein
levels are notoriously difficult to detect in HPV infected precancerous cells, and a direct
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relationship between E6 and E7 RNA levels and oncoprotein levels has not been
determined.

Therefore, we assayed cellular surrogates of E6 and E7 oncoprotein

activities. E7 inactivation of pRb leads to increased p16 expression and p16 is a widely
accepted surrogate of HPV infection [73-76]. Thus, we evaluated the levels of p53 and
p16 in cells treated to activate or to inhibit EGFR signaling. The comparable levels of
p53 in treated NIKS-SG3 and NIKS was somewhat surprising and suggests that HPV16
E6 proteins are not robustly expressed in NIKS-SG3 cells. This is likely because this cell
line contains only 1-10 copy(s) of the viral genome per cell [135]. Additionally, levels of
E6 and E7 are kept tightly regulated by viral processes in non-transformed,
undifferentiated cells, further explaining the lack of difference in p53 levels between
NIKS and NIKS-SG3 (reviewed in [20]). Initial experiments showed no difference in
p53 levels following EGFR activation or inhibition for 72 hours in NIKS-SG3 (data not
shown). Because stimulation of p53 activity may be required to observe any virally
mediated changes in p53 protein levels following incubation with EGF or cetuximab, we
stimulated p53 activity by incubating cells with the DNA damaging agent, cisplatin.
Cells were pretreated with EGF or inhibitor for 48 hours then cisplatin was added to
induce DNA damage and enhance p53 levels and activation for the last 24 hours of
treatment. Nevertheless, MTT assay results from cells treated with cisplatin and those
without cisplatin exposure appeared similar. When normalized to ß-actin levels, total p53
levels in untreated cells were not significantly altered in HPV-positive NIKS-SG3 cells as
compared to HPV-negative NIKS cells (Fig. 3.7AB; compare lanes 1 and 2).

We

interpret this to mean that E6 levels are maintained at low levels in these cells and
therefore p53 levels are not noticeably affected. Although EGF stimulation for 48 hours
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led to a ~3.5-fold increase in E6 RNA (Fig. 3.2A), levels of p53 protein also increased on
average, which is not consistent with our hypothesis that downregulation of viral
transcript levels and presumed decrease in E6 protein would lead to decreased p53 levels
(Fig 3.7AB; compare lanes 2 and 3). These results may be independent of viral functions
and instead due to the fact that EGF treated cells are actively proliferative therefore
initiate DNA damage repair machinery more robustly.

Furthermore, while viral

oncogene RNAs were reduced by 50% when cells were treated 48 hours with EGFR and
MEK inhibitors, we detected no significant difference in p53 levels under similar
conditions (Fig 3.7A).

Figure 3.7 HPV-infection does not significantly alter p53 levels in NIKS-SG3 cells but increases levels
of p16.
NIKS-SG3 cells were treated with cetuximab or EGF for 72 hours. Protein levels of p53, p21 (A), p16 (C)
and ß-actin were assessed by immunoblot in NIKS (N) or NIKS-SG3 treated with media alone (M), 10
ng/ml EGF (E), 100 µg/ml cetuximab (C); fold change of p53 and p21 levels (B) and p16 levels (C) were
analyzed from three separate experiments. Error bars = SEM.
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Interestingly, a significant upregulation of p16 was seen in mock-treated NIKSSG3 cells as compared to NIKS suggesting more robust expression of active E7 protein
in the NIKS-SG3 cells (Fig. 3.7CD; compare lanes 1 and 2). Although EGF exposure
increased E7 transcripts by ~1.5 fold after 2 days, p16 levels were not significantly
changed upon EGF stimulation (Fig 3.7CD; compare lanes 2 and 3).

However,

cetuximab treatment decreased p16 levels in NIKS-SG3 to near those in the parental cell
line, NIKS (Fig. 3.7CD; compare lanes 1 and 4). This decrease in p16 levels corresponds
with the downregulated E7 transcript levels seen following EGFR inhibition (Fig 3.7A)
and indicates a corresponding reduction in E7 protein levels. Furthermore, these data
indicate that inhibition of EGFR can have antiviral effects on infected cells even in cases
of low levels of viral activity.

3.3.7 EGFR Inhibition Sensitizes HPV-Positive Cells to Apoptotic Stimuli
Cisplatin, a DNA cross-linking agent, induces the formation of DNA adducts that activate
p53 leading to apoptosis in cells with normal tumor suppressor functions and catastrophic
DNA damage in highly proliferative cells lacking wild-type p53 [155]. As another
measure of viral oncoprotein depletion and tumor suppressor protein restoration, we
sought to determine if cetuximab-induced reduction of viral oncogene expression levels
could sensitize cells to DNA damaging agents. NIKS-SG3 cells were pretreated with
cetuximab for two or six days prior to cisplatin exposure, were treated concurrently with
cetuximab and cisplatin, or treated with cisplatin alone. Cell viability was determined at
72 hrs post cisplatin treatment at the timing indicated in Fig. 3.8A.

53

Figure 3.8 EGFR inhibitors sensitize HPV16-positive cells to apoptotic stimuli.
(A) Experimental design. (B) NIKS-SG3 cells were left untreated or exposed to cetuximab at the indicated
concentrations for 6 or 2 days prior to, or concurrent with cisplatin treatment. Cell viability was determined
by MTT assay 72 hr after cisplatin treatment. Error bars = SEM, *p<0.05. Data are the result of 1
experiment preformed in triplicate.

NIKS-SG3 cells treated only with cisplatin showed minimal loss of viability (Fig. 3.8B).
Cells treated concurrently with cisplatin and cetuximab had only a slight reduction in
viability as compared to media alone or cisplatin alone, concurrent delivery of cetuximab
and cisplatin together showed no benefit over either agent alone. As expected from
figure 3.4A, treatment with cetuximab alone resulted in ~50 – 75% loss of viability for 2and 6 day pretreatment, respectively, when compared to the media only control. When
cetuximab was administered as a neoadjuvant to cisplatin, further loss of viability was
seen at both concentrations of EGFR inhibitor. Loss of viability in the neoadjuvant
groups was significantly greater in the group receiving the higher dose of cetuximab.
These results indirectly support our corollary hypothesis that EGFR inhibition has

54

antiviral effects that restore tumor suppressor activity. Surprisingly, we did not observe a
dose response to cetuximab. As the MTT assay does not directly measure cell death, this
experiment might be best repeated using a clonogenic assay to evaluate the effects of
cetuximab. Testing the ability of cetuximab to sensitize cells to ionizing radiation rather
than cisplatin would also be informative. Additionally, this loss of viability could be due
to recovery of pRb functions as well, as we saw reduction of the p16 levels in HPVpositive NIKS-SG3 following cetuximab treatment (Fig 3.7AB). In continuing this work,
it will be important to determine which viral and cellular components are most affected
by cetuximab-induced HPV oncoprotein downregulation.

3.4 Discussion
HPVs are the infectious agent responsible for multiple types of squamous cell carcinomas
including cervical, anogenital and oropharyngeal [5, 6 zur Hausen, 2009 #3649, 7, 139].
Most HPV infections resolve without medical intervention. However, persistent infection
with HPV increases the potential of developing a pre-cancerous or malignant lesion. In
this study we demonstrated that the EGFR pathway is important in the regulation of
HPV16 oncogene transcription and maintenance of viral genome levels. Importantly,
inhibition of this pathway has antiviral effects suggesting that EGFR activation plays a
role in maintenance of infection and may be a critical vulnerability.
This work shows that positive feedback between EGFR signaling and HPV16
oncoproteins is subtle in preneoplastic cells.

Unlike previous studies using ectopic

overexpression of viral oncoproteins, our HPV-positive cell line did not exhibit the
expected degree of EGFR pathway upregulation when measured by flow cytometry and
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immunoblot in cells from subconfluent monolayers. We detected slightly lower levels of
cell surface-associated EGFR in our HPV-positive cell line (Fig 3.3A). And while we
occasionally observed heightened EGFR and ERK1/2 activation in NIKS-SG3 cells as
compared to NIKS cells, overall, EGFR-signal transduction was not significantly
elevated in HPV-positive cells (Fig 3.5BC).

The HPV-positive NIKS-SG3 cells

demonstrated higher viability when grown in the presence of EGFR and MEK inhibitors
than did NIKS cells (Fig 3.4). This indicates that HPV infection imparts growth factor
independence in proliferating cells that maintain episomal HPV genomes, agreeing with
previous reports by other labs.
HPV16 E6 and E7 have been shown to upregulate EGFR signaling [122, 123].
Additionally, viral oncoprotein E5 increases recycling of EGFR augmenting membrane
availability of the receptor [63-67, 72]. There are a number of caveats to those studies.
Previous studies have examined the interaction between single HPV oncoproteins and the
EGFR pathway, usually employing ectopic over-expression of the viral proteins.
Additionally, many of the previous studies have used cell types not typically targeted by
HPV in a natural infection. To our knowledge, ours is the first study examining the
interplay between high-risk HPV and EGFR signaling to utilize relevant cell types
carrying the entire HPV genome to model pre-neoplasia.

Additionally, our use of

isogenically matched HPV-negative and HPV-positive cell lines enables us to directly
address differences due to viral effects in our model. Compared with the previously
described effects of HPV16 oncoproteins on EGFR signaling, our data suggest that the
effect of viral oncogenes on the EGFR pathway is subtle in proliferating cells modeling
persistent infection. These results reinforce the importance of evaluating viral gene

56

function in the context of “normal” virus replication rather than in systems overexpressing a single or multiple viral genes.
We found that EGFR activation positively affected HPV oncogene transcript
levels in NIKS-SG3 cells. NIKS-SG3 cells carry HPV16 genomes extrachromosomally
in the background of a near-diploid immortalized human foreskin keratinocyte cell line.
As this cell line is capable of carrying out late viral life-cycle events in the raft system
[135], it represents persistently infected, preneoplastic keratinocytes. Previous studies
have shown that EGFR signaling can modulate HPV early transcription in keratinocytes.
Our findings agree with a previous study showing that EGFR activation by its cognate
ligand resulted in increased HPV16 E6/E7 transcript levels in the SiHa cervicalcarcinoma derived cell line as soon as 2 hours post ligand addition [130]. Another study
demonstrated that 48-hr EGF exposure of PHK160b, a cell line derived from primary
epidermal keratinocytes immortalized by transfection with wild-type HPV16 genome,
resulted in down-regulation of HPV early transcripts E6/E7 as assayed by northern blot
[134]. This effect of EGFR stimulation was seen concurrently with an EGFR activationinduced increase in cell proliferation and c-myc expression. Both of these previous
studies utilize cell lines immortalized by HPV16 and harbor integrated viral genomes.
SiHa cells contain 1.5 viral genomes by whole genome sequencing, the viral genome
structure and copy number for the PHK160b cells is not published [156]. The differences
reported by these authors could be due to differences in the LCR of the viral genomes or
integration sites.

Integration of HPV into the host genome is random although

chromosomal fragile sites appear to be preferred [37, 157, 158]. Loss of the LCR
upstream of viral genes could occur via a break in the viral DNA downstream of this
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region prior to integration. Methylation of the viral LCR in integrated HPV genomes has
also been shown to cause loss of function [157]. Additionally, insertion of the viral
genome downstream of a strong host promoter could drive viral oncogene transcription
even in the presence of a functional LCR [159, 160]. Further analysis of the differences
in cellular genomes, proteomes and methylomes among these cell lines may help to
reveal the molecular basis for these differing results.
We detected several antiviral effects of EGFR and MEK inhibition. Inhibition of
EGFR signal transduction in NIKS-SG3 cells results in reduction of viral oncogene
transcript levels, confirming our hypothesis that the EGFR pathway is important in the
control of viral transcription (Fig 3.5A). We also discovered that this control of viral
transcription is mediated through the MEK1/2 signaling pathway (Fig. 3.5B). Notably,
we showed that inhibition of the EGFR pathway reduced the viral genome load in NIKSSG3 cells (Fig. 3.6). The decrease in viral early transcript levels preceded the decreased
genome levels (Fig. 3.5A and B compared with Fig. 3.6) suggesting that the loss of early
protein expression results in the inability of the virus to replicate its genome. Transcripts
thought to encode early viral proteins E1 and E2 are expressed from the same viral
promoter as E5, E6 and E7 and are necessary for the replication and maintenance of viral
genomes (reviewed in [18] and [17]). Therefore, an EGFR/MEK inhibitor-mediated
decrease in early gene expression, including E1 and E2, might underlie the loss of viral
genomes.
We detected antiviral effects of EGFR and MEK inhibition with regard to tumor
suppressor functions. First, enhancement of viral E7 function following EGFR activation
was observed in the NIKS-SG3 cell line by assessing cellular p16 levels (Fig. 3.7B). The
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downregulation of p16 following cetuximab treatment further indicates that inhibition of
EGFR activation downregulates E7 activities in actively infected cells and likely restores
cell cycle regulation. Although RNAs with potential to encode E6 were downregulated
with EGFR inhibition, we saw no change in p53 levels. This could be because E6 protein
levels are low in NIKS-SG3 cells. However, our finding that pretreatment of HPVpositive cells with cetuximab sensitized cells to the DNA-damaging effects of cisplatin
(Fig 3.8) indirectly suggests that p53 levels and/or function were increased in the context
of EGFR inhibition and antiviral effects. DNA-damage induced apoptosis that results
from cisplatin exposure can be p53-mediated [155] therefore recovery of cellular p53 in
these cell lines may be responsible for the increase in cell death in the cetuximabsensitized cells. A similar loss of cell viability was obtained by Woodworth et al. in
HPV16 E6/E7 expressing cervical epithelial cells treated with the EGFR inhibitor
erlotinib [161]. Although previous reports indicate that cisplatin can activate EGFR
[162]; other studies have shown that cetuximab can inhibit this activity [163, 164].
Therefore, we do not believe this mechanism complicate our interpretation.
It might, nevertheless, be informative to repeat our experiment using ionizing
radiation as the DNA damaging agent rather than cisplatin to avoid unintended EGFR
activation. As we saw little HPV-associated downregulation of p53 in NIKS-SG3 cells,
testing the ability of cetuximab to induce p53 recovery in a more robust system such as a
preneoplastic cell line with higher HPV16 genome copies or an HPV-positive cancer cell
line would also be beneficial. Our results are consistent with the findings of Meira, et al.
who showed increased cytotoxicity in the HPV-positive CaSki cervical cancer cells in
response to radiation or chemotherapy following pretreatment with cetuximab [165].
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Although they did not investigate viral expression, their study suggests that the
mechanism of sensitization is maintained even after oncogenic transformation. Our
results are also in accord with Kimple et al, who found increased radiation sensitivity in
cells expressing HPV16 E6 despite the effect of E6 to degrade p53. This suggests that
low levels of normally functioning p53 in HPV-positive HNC cells could be activated by
radiation, leading to cell death [166].
Taken together, the results of this study indicate that the EGFR pathway is
important in the maintenance of HPV infection including expression of viral oncogenes
and genome replication. This has implications in both active infections with high-risk
HPV as well as HPV-positive carcinomas. We suggest that EGFR signaling enhances
transcription of viral early genes enabling genome replication and persistent infection of
the host cells. Our work also has significant implications regarding the importance of
cofactors in the progression to HPV-associated cancers. Numerous predictive cofactors
have been identified for cervical cancer including: parity, coinfection with other sexually
transmitted infectious agents, and history of smoking [167, 168]. These cofactors may
activate growth factor receptor pathways, possibly enhancing the expression of HPV
oncogenes though mechanisms we have outlined herein, priming the cells for malignant
transformation. In HPV infections and associated cancers, understanding the role of
EGFR in maintaining viral oncoprotein levels may help to design more effective
treatments and refine current treatment protocols. In productive infections, including
cutaneous warts, genital warts, and recurrent respiratory papillomatosis (RRP), treatment
with an EGFR or MEK inhibitor may be an alternative to current cryotherapy and
surgical approaches, which result in high morbidity. In fact, several cases of RRP have
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been successfully treated with the EGFR inhibitor erlotinib [169-171].

Additional

clinical studies are needed to determine safety and long-term efficacy of these treatments.
Cetuximab is already used in the treatment of HNSCC in conjunction with
chemotherapy/radiation and some benefit has been shown for patients with advanced
stage HPV-positive cancers over HPV-negative [172, 173]. However, previous clinical
trials using concurrent cisplatin plus cetuximab or cetuximab as a monotherapy in
cervical cancer have failed to show a therapeutic benefit for the use of EGFR inhibitors in
their patient populations [174, 175].

It should be noted that cetuximab was given

concurrently with cisplatin in these trials. Our data suggest cetuximab is likely to be
more effective given as a neoadjuvant to induce antiviral effects prior to receiving
chemoradiotherapy. Further investigation into the effect of EGFR/MEK inhibitors on
viral activities driving HPV-positive cancers may be important in determining patient
populations that will most benefit from these treatments.

3.5 Limitations of this study
While this study provides significant insight into the interplay between HPV and the
EGFR pathway, it contains limitations. This study was carried out in a keratinocyte cell
line harboring episomal HPV at low copy numbers. This cell line was selected due its
ability to maintain episomal HPV genomes as well as recapitulate the viral life cycle in
the organotypic raft system [135]. Therefore, we anticipated that this cell line, when
grown in monolayer, would be an appropriate model for actively infected cells in the
basal layer of the epidermis. In our study, these cells were maintained at subconfluent
densities to avoid contact inhibition of growth. In our system, we failed to observe the
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expected decrease in p53 levels in HPV-positive cells as compared to their parental cell
line. However, a recent publication by Isaacson Wechsler et al. showed that in similar
cells, growth to confluence was required for virally mediated downregulation of p53
levels [176]. For the most physiologically relevant model available, these cells should be
grown in the organotypic raft system, which recapitulates stratified epidermis. Effects of
EGFR activity on viral transcription can then be assessed at different points in the viral
lifecycle. Additionally, as our cell lines did not robustly express E6 (based on the lack of
observable downregulation of p53 levels), use of a more robust model system such as a
cell line modeling an HPV-positive high-grade intraepithelial neoplasia or cancer cell line
maintaining episomal genomes would be informative.

Lastly, we showed that

pretreatment of NIKS-SG3 cells sensitized cells to cisplatin, however the contribution of
viral oncoprotein levels to this effect was not analyzed.

This needs to be further

evaluated, perhaps by siRNA inhibition of E6 and E7, to determine whether our result
reflects viral oncoprotein downregulation or rather is a more general result of growth
factor deprivation.
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CHAPTER 4 - Evaluation of Anti-Viral Effects of the EGFR-Inhibitor Cetuximab in
HPV-Positive Xenografts
Abstract
Head and neck cancer (HNC) is the 6th most common cancer worldwide. Historically,
HNCs have been associated with a history of tobacco and alcohol use. However, there is
a growing HNC patient population wherein their cancer is associated with human
papillomavirus (HPV) infection. Approximately 30% of all oropharyngeal squamous cell
carcinomas (OPSCCs) are HPV-positive, of these, HPV16 accounts for 90% of cases.
Patients with HPV-positive OPSCC have a better prognostic outcome than patients with
HPV-negative HNC.

Numerous differences exist between HPV-positive and HPV-

negative OPSCC yet the standard of care treatment is the same regardless of HPV-status.
The EGFR inhibitor, cetuximab, is the only targeted therapy FDA approved for OPSCC.
We have previously shown that inhibition of EGFR/MEK signaling by cetuximab
downregulates viral oncogene expression in vitro in a model of preneoplasia. In this
study, we sought to determine if cetuximab exhibited anti-viral effects in vivo, including
downregulation of viral oncogene expression and restoration of the tumor suppressor p53,
which is degraded by viral oncoprotein E6. Our study reveals that EGFR/MEK inhibition
inhibits growth of HPV-positive xenografts and can lead to downregulation of viral
oncogene expression in vivo. Furthermore, downregulation of the AP-1 transcription
factor c-Fos appears to be associated with the antiviral effects. Administration of the
MEK inhibitor, trametinib, exhibited dramatic antiviral effects in xenografts from a
moderately cetuximab resistant HNC cell line indicating that treatments targeted
downstream of EGFR may also be a viable therapeutic target in HPV-positive OPSCC.

63

4.1 Introduction
Head and neck cancer (HNC) is the 6th most commonly diagnosed cancer worldwide with
over 60,000 incident cases every year [177]. Over 95% of HNC are squamous cell
carcinomas (HNSCC). HNSCC are most commonly associated with heavy tobacco and
alcohol use [178]. Incident cases of HNSCC attributed to these traditional risk factors
have declined in the past 30 years, possibly due to public awareness of the risks of
tobacco use. However, total numbers of HNSCC have not shown an equivalent pattern of
decline [87, 179]. The reason behind this discrepancy is the rise in the number of HPVassociated HNSCC [87, 88, 179]. Currently, it is estimated that ~30-56% of HNSCC are
HPV-positive and HPV16 alone is involved in ~90% of HPV-associated oropharygeal
SCCs (OPSCC) [88].
HPVs are the most commonly acquired sexually transmitted infectious agents and
the majority of sexually active individuals will become infected at some point in their
lifetimes [81]. Oncogenic, or the so called “high-risk” HPVs are the causative agent of
numerous cancers including cervical, head-and-neck, anal, vulvar, and cancers of other
anogenital sites [5-7, 139].
High-risk HPVs encode three oncoproteins: E5, E6, and E7. E6 and E7 are each
able to induce cellular immortalization when overexpressed in vitro and are found
expressed at high levels in HPV-positive cancers [39-42]. These proteins have multiple
activities in the viral lifecycle, the outcomes of which are enhancement of cellular
proliferation and inhibition of cellular differentiation [140]. These functions are achieved
in part through association with and degradation of host cell cycle check point proteins
including p53, degraded by E6, and pRb, which is degraded by E7 [43, 44, 58, 141, 142].
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Genetic differences between HPV-positive HNSCCs and HPV-negative HNCs
include disparities in the mutational landscapes, chromosomal abnormalities and geneexpression profiles [180-184]. HPV-positive HNSCCs harbor fewer mutations than their
HPV-negative counterparts, an aspect attributed to HPV oncoprotein expression.
Importantly, HPV-positive HNSCCs maintain wild-type TP53 [182, 184].

The

dissimilarities in these cancers is also highlighted by disparate patient outcomes; patients
with HPV-positive OPSCCs tend to respond more favorably to treatment and have a
better prognosis compared to patients with HPV-negative HNCs [185-187]. Although
distinct genetic backgrounds likely play a role in outcome, the specific molecular
mechanisms imparting the biological differences between HPV-positive and HPVnegative OPSCCs are not well defined.
Current standards of care for the primary, nonsurgical management of previously
untreated, locally advanced HNSCC were developed during the era when HPV-negative
disease predominated. Despite the contrasts between these cancers, the standard of care
for locally advanced HNSCC (stage III-IVb), regardless of HPV involvement, is
concurrent cisplatin-radiotherapy [188]. Notably, HPV status is a major independent and
positive prognostic factor for patients with HNSCC, and these standards are likely to
represent overtreatment. In a multivariate analysis of RTOG 0129, where patients with
locally advanced HNSCC were treated with cisplatin-radiotherapy (RT), those with HPV
positive tumors had a 58% reduction in risk of death compared with patients with HPVnegative tumors (hazard ratio 0.42; 95% CI 0.27-0.66) [187]. Moreover, in the Bonner
trial, patients with HPV positive oropharyngeal tumors disproportionately benefitted from
the addition of cetuximab, a chimeric monoclonal antibody against the epidermal growth
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factor receptor (EGFR), to RT [91, 189]. In particular, the latter finding has been viewed
as a clinical paradox: in the context of chemoradiation, why is EGFR targeting more
effective in HPV-positive vs. HPV-negative tumors, when the purported target, EGFR,
demonstrates significantly lower expression in HPV-positive vs. HPV-negative tumors?
Previous studies have shown that HPV16 oncoproteins upregulate EGFR
signaling. Expression of E6 and E7 is reported to upregulate EGFR levels in cells [122,
123]. HPV16 E5 is also associated with upregulated EGFR signaling and recycling of the
receptor to the cell membrane following activation-induced internalization [63-67, 72].
The fact that all three of these oncoproteins function to enhance signaling through this
pathway suggest the EGFR signaling pathway must be important in the viral lifecycle.
Interestingly, the AP-1 family of transcription factors, which is modulated by EGFR
signaling, is important in regulating transcription of HPV early genes [127, 128, 130,
131, 190]. In particular, cFos expression increases transcription of HPV16 oncogenes
[128, 130, 131] and levels of cFos can be controlled by EGFR activity (reviewed in
[125]). De Wilde et al. showed that levels of AP-1 transcription factors are differentially
expressed in HPV-transformed cells as compared to normal and precancerous tissues, and
that cFos and JunB, specifically, are upregulated in cancerous cells [126].

Lastly,

suppression of HPV oncogene transcription can be mediated by downregulation of cFos
and JunB levels [191, 192].
Suppression of E6 and E7 levels in HPV-positive cancer cell lines by siRNA is
reported to induce apoptosis and have anti-tumorigenic effects. siRNA knockdown of
HPV E6 alone or in conjunction with E7 in HeLa and SiHa cells resulted in increased p53
levels and induction of cellular senescence and apoptosis in vitro [77, 78]. Furthermore,
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recent studies reported that in vivo siRNA knockdown of E6/E7 results in delayed tumor
growth, p53 recovery, and radiosensitization of SiHa and HeLa xenograft tumors [79,
80]. Together, these data demonstrate that decreasing levels of E6 and E7 proteins in
HPV-positive cancers has therapeutic effects.
As EGFR signaling is upregulated by HPV oncoproteins, we previously
hypothesized that HPV establishes a positive feedback loop with the EGFR pathway
resulting in upregulation of viral transcription and that inhibition of EGFR signaling
would have antiviral effects including downregulation of E6 and E7 expression and
recovery of p53 levels and activity. In chapter 3, we showed that activation of EGFR
signaling positively affected transcriptional activity of early genes including E6 and E7 in
a cell line containing episomal HPV16 genomes. Furthermore, we demonstrated that
blocking EGFR activation with cetuximab had antiviral effects including decreased viral
oncogene transcript levels and sensitization of cells to cisplatin. Studies from other labs
undertaken while we were conducting these experiments have shown that cetuximab is
able to decrease HPV-positive xenograft tumor growth rate [193, 194]. As HPV-positive
HNSCC do not typically overexpress EGFR and the ADCC component of cetuximab’s
mechanism of action is impeded in the immunocompromised animals used in these
studies, the mechanism behind cetuximab’s antitumor effects in these cohorts are not well
understood. Based on our previous studies, we questioned if downregulation of viral
oncogenes following cetuximab treatment might contribute to the antitumor effects in
these xenografts. We hypothesized that cetuximab-mediated EGFR inhibition would
downregulate viral oncogene expression in xenografts from cell lines maintaining viral
LCR-mediated control of viral transcription.
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Furthermore, we postulated that this

downregulation of viral oncoproteins would restore wild-type p53 expression and
downregulate p16 expression.
Herein we describe the effects of cetuximab treatment on viral oncogene
expression levels, viral activities, and related cellular targets in xenografts from four
HPV-positive cell lines. Different viral responses to cetuximab were seen among the cell
lines used. We observed decreased E6 and E7 RNA expression levels in two cell lines
treated with cetuximab or the MEK1/2 inhibitor, trametinib, and downregulation of viral
oncogene expression appeared to correlate with the ability of the drug to modulate levels
of AP-1 transcription factors, cFos and JunB. We also describe the histological effects of
cetuximab treatment on xenografts with disparate viral responses.

4.2 Methods
4.2.1 Cell Culture
SiHa and CaSki cells, derived from HPV16-positive cervical cancers, were obtained from
ATCC and maintained in MEM or RPMI-1640 containing 10% fetal calf serum (FCS),
respectively. UM-SCC47 and UM-SCC104 cell lines, derived from HPV16-positive
HNSCCs, were obtained from Dr. Thomas Carey’s laboratory (U. Michigan) and
authenticated by STR profiling (Table 2.1).

HNSCC cell lines were maintained in

DMEM containing 10% FCS. All cell lines were grown at 37°C, 5% CO2. Cell lines and
HPV status for each is listed in Table 4.1.
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Table 4.1 List of HPV-Positive Cancer Cell Lines Used
Cell Line

HPV Status
(Variant)a

Source

Viral Genome
Copy Number
qPCRb

Viral Genome
Copy Number
WGSc

References

SiHa

HPV16
(EUR)

Cervical

0.397

2

[156, 195]

CaSki

HPV16
(EUR)

Cervical
(small bowel
metastasis)

122

831.6

[156, 196]

UM-SCC-47

HPV16
(AFR2a)

Lateral tongue

21.1

47

[156, 197]

UM-SCC-104

HPV16
(EUR)

Floor of mouth

2.86

1.1

[156, 198]

a

HPV variant: (EUR) European; (ASN) Asian; (AFR) African. Nomenclature is based on variants in E6 and LCR regions by the
IARC HPV Variant Study Group [199].
b
Viral copy number as measured by real-time PCR. Copy number reflects the ratio of HPV16 E6 to Endogenous retrovirus 3
gene (ERV3).
c

Viral copy number as determined by whole-genome sequencing (WGS).
Adapted from [199]

4.2.2 Xenograft Preparation
Cell lines derived from HPV-positive cervical cancers (SiHa, CaSki) or HNSCC (UMSCC47, UM-SCC104) were trypsinized and resuspended in appropriate cell culture
media. To establish xenografts, cells (1–2 x 106) mixed 1:1 with Matrigel (BD
Biosciences) were injected subcutaneously into flanks of 8-10 week old, female
NOD/SCID-gamma (NSG) mice. Once tumors were palpable, they were measured by
caliper, stratified by size, and animals randomized into treatment and control groups.
Cetuximab (1, or 5 mg/kg) or 0.9% saline control was administered 3x/week by i.p.
injection. Trametinib (1 mg/kg) or vehicle control (10% Cremophor EL, 10% PEG 400)
was administered daily by oral gavage. Tumors were measured by caliper 3x/week and
volumes calculated using the formula: length x width x width/2.
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Xenografts were

harvested when the control group reached 1 cm in size.

Tumors were surgically

removed, divided for histology, RNA, and protein extraction and flash frozen in liquid
nitrogen. The Institutional Animal Care and Use Committee of the University of New
Mexico Health Sciences Center (Albuquerque, NM) approved all animal procedures.
4.2.3 RNA Extraction
Total RNAs were extracted from frozen tumor portions using Direct-zol RNA MiniPrep
kit (Zymo) according to manufacturer’s protocol. Briefly, frozen tissues were weighed,
thawed in TriReagent (at least 1ml Trizol per 100mg tissue) (Sigma) and homogenized
using a Pro200 rotory homogenizer (Pro Scientific). Lysates were held at 4°C overnight.
Non-soluble material removed by centrifugation (12K x g for 10 minutes at 4°C) and
supernatant was transferred to a fresh tube. An equal volume of 100% ethanol was added
to supernatant to precipitate nucleic acids. Solution was added to Zymo column and
washed. Following wash steps, RNA was eluted in RNase-free dH2O.

DNA was

removed by DNase treatment (TURBO DNA-free, Ambion). Quality and concentration
of RNA was determined by spectrometry (Nanodrop, BioRad) and agarose gel
electrophoresis as described in [138].
4.2.4 RT-qPCR
cDNA was prepared from 0.2 (UM-SCC47, 5 mg/kg cetuximab cohort) – 0.5 mg of total
RNA using M-MLV reverse transcriptase and random hexamer primers (Applied
Biosystems). 25ng of template was used for each qPCR reaction (10ng for UM-SCC47,
5mg/kg cetuximab cohort). Sequences and concentrations of primers and probes as well
as PCR cycle profiles are provided in Table 2.1. For hydrolysis probes, iQ master mix
(BioRad) was used. E6, E7, and cFos primer sets were run with SsoFast Evagreen master
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mix (BioRad). JunB primers were obtained from Applied Biosystems and used with
TaqMan Fast Advanced Master Mix (Applied Biosystems). All qPCR reactions were run
on CFX96 thermocycler (BioRad) and data analyzed using BioRad CFX Manager
(version 3.1.1517.0823).

Cq values for targets were normalized to human B-actin

expression levels using the ΔCq method.
4.2.5 Immunohistochemistry
Formalin-fixed paraffin embedded (FFPE) blocks were sectioned at 5 μm thickness and
transferred to charged slides (Fisher Scientific). Sections were deparaffinized in Citrisolv
(Fisher Scientific) and rehydrated through 70% ethanol followed by 10 minutes in dH2O
(for H&E) or 1X PBS (for IHC). For manually stained IHC slides, antigen retrieval was
performed by boiling slides in appropriate buffer for indicated times (see Table 2.3).
Blocking was performed in 5% normal horse serum (Vector Labs), 1 hour at room
temperature. The following antibodies were used for IHC: total-EGFR (Cell Signaling),
phospho-EGFR(Y1173) (Cell Signaling), phosphor-p44/42 (Cell Signaling), Ki-67 (BD
Biosciences/Thermo Scientific), p16INK4a (Roche/Ventana, performed by UNM Human
Tissue Repository), p53-D07 (Novocastra, performed by MD Anderson Research Park
Histology Core), human mitochondria marker (Chemicon, performed by MD Anderson
Research Park Histology Core). Manually stained sections were incubated with primary
antibody in blocking solution overnight at 4°C in a humidified chamber (see Table 2.4 for
antibody concentrations). Slides were washed in TBS-T, and incubated with biotinylated
anti-mouse/rabbit secondary antibody (VECTASTAIN Elite Universal ABC Kit, Vector
Labs) for 30 minutes followed by 30 minutes incubation with ABC reagent. Sections
were incubated with DAB (Vector Labs) for 15 minutes. Slides were counter stained
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with hematoxylin, dehydrated and cleared in Citrisolv. Coverslips were mounted with
Permount mounting media.
4.2.6 Histological Evaluation
Blinded sections were evaluated and all HALO analysis was perfromed by a certified
pathologist (Dr. Donna Kusewitt of the UNM Comprehensive Cancer Center). IHC
stained tissues were assigned a score between 0-3 based on epithelial staining intensity
with 0 representing the lowest intensity and 3 representing the strongest. For evaluation
of tissue morphology, Aperio-scanned H&E-stained slides and the HALO (Indica Labs)
morphometry system were used. The entire tumor mass was outlined to obtain the total
tumor area. HALO was then trained to recognize viable tumor epithelium, keratin,
stroma, large blood vessels, and background (no tissue) within the tumor. Necrotic areas
within the tumor epithelium were outlined by hand for exclusion in calculations. HALO
was reprogramed for each cell line because of vastly different morphologies. HALO
determined the area of these components and percentage of the entire tumor occupied by
these areas was calculated by the pathologist. Areas of tumor epithelium were confirmed
by IHC for human mitochondrial marker (shown in Supp Figs 1 and 2). Ki67 IHC slides
were also scanned into Aperio and analyzed using HALO. HALO was trained to
recognize epithelium and then to identify Ki67-positive nuclei in that epithelium. Positive
nuclei were classified as strongly (+3), moderately (+2), or weakly (+1) positive
(considered background). The number of strongly and moderately positive nuclei (+2,
+3) were normalized to the area of the epithelium.
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4.2.7 RNAscope® - RNA in situ hybridization
FFPE sections were stained according to manufacturer’s protocol (2.5 HD Detection Kit
– Brown) using a probe to high-risk HPV E6/E7 (hrHPV 7, Advanced Cell Diagnostics).
Briefly, fresh cut sections were deparaffinized in xylenes (2 x 5 minutes each) and
washed in 100% ethanol (2 x 1 minutes each). Exogenous peroxidase was quenched by
incubation with 3% H2O2 (Advanced Cell Diagnostics) for 15 minutes then washed with
dH2O. Slides were submerged in sub-boiling temp Antigen Retrieval Buffer (Advanced
Cell Diagnostics) for 15 minutes followed by washing in dH2O then 100% ethanol.
Tissues were encircled with a hydrophobic pen and slides were allowed to dry overnight.
Slides were incubated in protease (Advanced Cell Diagnostics) 30 minutes, 40°C then
washed in dH2O. High risk HPV E6/E7 probe was hybridized for 2 hours at 40°C. AMP
steps 1- 4 were performed for recommended lengths of time at 40°C, with 2 minute
washes in 1x Wash Buffer (Advanced Cell Diagnostics) between each amplification step.
The final two AMP steps (5 and 6) were performed at ambient temperature for
recommended times, slides were washed with 1x Wash Buffer after each step. Signal
detection was performed with DAB (Advanced Cell Diagnostics) for 10 minutes at
ambient temperature. Tissues were counterstained with 50% Gil’s hematoxylin solution,
coverslipped and allowed to dry overnight. Slides were digitally scanned (Aperio Slide
Scanner) and analyzed using HALO software by Dr. Kusewitt.
4.2.8 Statistical Analysis
All statistics for growth curves and RT-qPCR experiments were performed in GraphPad
Prism version 6.0g for Mac.

Growth curves were compared by multiple t-tests

(unpaired). RT-qPCR data were compared by t-test. Correlation between tumor size and
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transcript expression levels was determined by Spearman’s r test. Statistical outliers
were determined for each experimental group using Grubb’s outlier test (GraphPad
Prism) and outliers were removed from the datasets. Semi-quantitative histology results
were compared using the Mann-Whitney test. Error bars represent the standard error of
the mean (SEM) for each group. p-values of less than 0.05 were considered to be
statistically significant.
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4.3 Results
4.3.1A Effect of Cetuximab Treatment on Viral Oncogene Expression in UM-SCC47
Tumor Xenografts
The UM-SCC47 cell line is derived from an HPV16-positive lateral tongue lesion and
produces moderately differentiated xenograft tumors.

It was recently described as

moderately resistant to cetuximab by dose response in vitro as compared to other HNSCC
cell lines [200]. Consistent with this, we found treatment with a 1 mg/kg dose of
cetuximab 3x/week for 4 weeks had no effect on tumor growth rate in the UM-SCC47
tumor-bearing cohort (Fig 4.1A) and no change in E6 or E7 expression levels was
observed (Fig 4.1B).

Figure 4.1 Low-dose cetuximab does not affect tumor growth or viral oncogene levels in SCC47
xenografts.
NSG mice bearing SCC47 xenografts implanted subcutaneously were given cetuximab (1 mg/kg) or
vehicle only (0.9% saline) 3x/week. Tumors were measured 3x/week by caliper and percent growth from
treatment start (time=0) are shown in (A). RNA from homogenized tumor sections was analyzed by RTqPCR for expression levels of viral oncogenes E6 and E7 and transcript levels were normalized to human
β-actin transcript levels. The average expression levels of normalized E6 and E7 from the vehicle tumors
was set to 1 and data shown as fold-change compared to control (B). Error bars = SEM, statistical
significance assessed by Student t-test.

However, a dosage of cetuximab at 5 mg/kg significantly inhibited tumor growth over 3.5
weeks (Fig 4.2A, final tumor weights shown in 4.2B). We observed that the amount of
RNA recovered from the high-dose cetuximab treated tissues was low as compared to
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yield from other tumors of the same weight. For this reason, cDNA from 10ng of total
RNA template was used for each RT-qPCR reaction. Due to the low amount of template,
levels of E6 and E7 transcripts had Cq values of >30, near the detection limit for the
assay, and β-actin levels for these were also low but within the detection range (data not
shown). When E6 and E7 transcript levels were normalized to β-actin, we observed no
change in viral oncogene transcript levels in tumors between vehicle and cetuximab
treated mice (Fig 4.2C). There was no correlation between E6/E7 expression levels and
tumor growth or final tumor weight (Fig 4.2D, E). This indicates that cetuximab has antitumor effects independent of the level of viral oncogene expression.
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Figure 4.2 Cetuximab delays tumor growth independent of normalized viral oncogene expression
levels in SCC47.
NSG mice bearing SCC47 xenografts implanted subcutaneously were given cetuximab (5 mg/kg) or
vehicle only (0.9% saline) by i.p injection 3x/week. Tumors were measured 3x/week by caliper and
percent growth from treatment start (time=0) are shown in (A). Final tumor weights (in grams) at necropsy
are shown (B). RNA from homogenized tumor sections was analyzed by RT-qPCR for expression levels of
viral oncogenes E6 and E7, and AP-1 transcription factors cFos and JunB. Transcript levels were
normalized to human β-actin transcript levels. The average expression levels of normalized target from the
vehicle tumors was set to 1 and data shown as fold-change compared to control. Relative expression levels
of E6 and E7 are shown in (C). Relative levels of E6 and E7 transcripts were plotted against the change in
tumor volume over the course of treatment (D) or the final tumor volume (E) and linear correlation
assessed by Spearman’s r test. Relative expression levels of cFos and JunB are shown in (F). Relative
levels of E6 and E7 transcripts were plotted against the expression levels of cFos (G) and JunB (H) and
linear correlation assessed by Spearman’s r test. Error bars = SEM, Statistical significance assessed by
Student t-test, *p≤0.05, **p≤0.01.
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There is compelling evidence that EGFR signaling controls AP-1 transcription
factors that subsequently regulate HPV oncogene expression. Many studies have shown
that the AP-1 family of transcription factors is important in regulating transcription of
HPV early genes [127-129, 131]. Another study demonstrated that EGFR-activation can
mediate upregulation of AP-1 transcription factors leading to enhanced HPV early gene
expession [130]. Several additional groups have shown that expression levels of several
AP-1 transcription factors, including cFos and JunB, are dysregulated in HPV-positive
cervical cancer [126, 131, 192]. Unexpectedly, we observed no significant change in the
levels of either cFos or JunB transcription factor RNA in the tumors from cetuximabtreated mice (Fig 4.2F). An explanation for this finding may be due to the fact that
ERK1/2 activation in SCC47 cells is partially resistant to EGFR inhibition. Indeed, a
previous study reported that, treatment of SCC47 cells in vitro with cetuximab and/or
trastuzimab, which targets ErbB2, failed to inhibit ERK1/2 activation [201]. There was
no significant correlation between E6/E7 transcript levels (Fig. 4.2G, H), which were also
unchanged by cetuximab treatment.
4.3.1B UM-SCC47 Biomarker Detection by Histology and IHC
The SCC47 high-dose cetuximab cohort was selected for histological analysis.

As

mentioned previously, SCC47 is an HPV16-positive cell line that yields moderately
differentiated tumors.

Treatment of SCC47 xenografts with high dose (5mg/kg)

cetuximab resulted in significant reduction of tumor growth as compared to controls (Fig
4.2A, B) but produced no noticeable change in viral oncogene RNA levels (Fig 4.2C).
As expected, SCC47 xenograft tumors treated with cetuximab showed an average
of less than half of the total epithelial area as compared to the control group (Fig 4.3A
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and B).

Untreated xenografts appeared moderately differentiated with stratified

epithelium surrounding areas of accumulated keratin. Intermediate layers of epithelium
in the untreated group were markedly thickened, indicating hyperplasia (Fig 4.3A).
Cetuximab treatment induced further differentiation of epithelium in treated tumors, as
seen by few stratified layers of epithelium and higher levels of keratin deposits in H&E
stained sections (Fig 4.3A and B). In fact, the bulk of the cetuximab treated tumors was
composed of keratin deposits and not epithelium (Fig 4.3B).

Additionally, tumors

exposed to cetuximab had more than twice the stromal makeup compared to control
tumors. None of the tumors exhibited signs of necrosis. The high ratio of keratin to
epithelium explains the low RNA yield obtained from the cetuximab treated tumors.
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Figure 4.3 Cetuximab treatment induces differentiation and morphologic changes in SCC47
xenografts.
FFPE sections of xenografts from cetuximab and control tumors were H&E stained, representative images
for vehicle and cetuximab sections are shown (A). Slides were scanned using an Aperio slide scanner and
percent tumor composition determined using HALO software. Results are summarized in (B).
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The IHC results reported in Figures 16-17 are summarized in Table 2. Tumors
from mice treated with cetuximab showed slightly decreased EGFR staining and
importantly, phospho-EGFR staining was lower in those receiving EGFR inhibitor than
in untreated controls (Table 2 and Fig 4.4A and B). This indicates that cetuximab
diminished the total and active levels of EGFR. EGFR staining in both groups was
largely restricted to the cell periphery indicating localization of the receptor to the plasma
membrane. In the well-differentiated epithelium, only the basal layer of cells were
EGFR-positive while the majority of the thickened epithelium in the untreated tumors
stained positive for EGFR (Fig 4.4A).

Table 4.2 IHC Scores for UM-SCC47 5mg/kg Cetuximab Cohort

Interestingly, cetuximab treatment also led to decreased intensity of phospoERK1/2 by approximately half in SCC47 xenografts compared to that in vehicle treated
controls (Fig 4.4C). It should be noted that there was extensive staining of the upper
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layers of epithelium with this ERK1/2 antibody, which may be a staining artifact.
Staining for ERK1/2 in tumors from the cetuximab treated animals was restricted to these
upper layers while tumors from control animals exhibited staining throughout multiple
epithelial layers. The decreased ERK1/2 staining in tumors from the cetuximab-treated
group seems contradictory to the report of sustained ERK1/2 activity in SCC47 cells in
monolayer culture even after cetuximab or trastuzimab treatment [201]. Together, these
data suggest that cetuximab deprives the tumor cells of growth factor stimulation
resulting in differentiation.
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Figure 4.4 Cetuximab decreases levels of active EGFR and ERK1/2 in SCC47 xenografts.
FFPE sections from cetuximab treated and control tumors were stained by IHC for total EGFR (A),
phospho-EGFR(Y1173) (B), and phospho-ERK1/2 (C). Representative images of each treatment group are
shown for each target. Staining intensity was scored from 0-3, with 3 indicating the strongest signal.

To evaluate the effects of cetuximab on viral activity, we analyzed levels of
p16INK4a, p53, and Ki67. Expression of p16 is often elevated in HPV-positive cancers and
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p16 detection is commonly used as a surrogate marker of HPV-positive tumors [73-76].
Surprisingly, even though we measured no change in viral oncogene expression in tissue
extracts by RT-qPCR, we did observe decreased p16 staining in cetuximab treated
xenografts (Fig 4.5A). In cetuximab treated tumors, p16 staining was restricted to the
basal layers of epithelium (Fig 4.5A). Conversely, control tumors exhibited staining
throughout the basal and intermediate layers of epithelium.
Both control and treatment groups contained epithelium with p53-positive nuclei,
but p53 staining intensity was higher in the control group than in the cetuximab treated
cohort (Fig 4.5B). Additionally, in untreated tumors, nuclei in the upper layers of the
epithelium stained positive for p53 expression while nuclei in the lower layers of
epithelium where negative. The cetuximab treated xenografts contained mostly basal
cells and only few of those exhibited p53 expression. The p53 staining pattern in the
untreated xenograft tumor group is reminiscent of that observed when the W12E cervical
cancer cell line, which maintains episomal HPV16 genomes, was cultured as
differentiated epithelium in the raft system [202, 203]. Staining for p53 in these tissues is
restricted to cells in the upper layers of epithelium, suggesting recovery of p53 levels as
viral oncogene expression is downregulated concomitant with cellular differentiation.
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Figure 4.5 E6/E7 expression and p53 levels change concomitant with cellular differentiation in
SCC47.
FFPE sections were stained by IHC for p16INK4a (A) and p53 (D07) (B) and staining intensity was scored
from 0-3, with 3 indicating the strongest signal and scores are summarized in graphs. (C) IHC for Ki67.
Slides were scanned using an Aperio slide scanner and staining analyzed using HALO software. Number
of total Ki6-positive cells for each tumor are shown in the top graph while number of Ki-67-positive cells
normalized to epithelial area for each tissue section is shown in the bottom graph. (D) RNA ISH was
performed to determine spatial expression of HPV E6 and E7, black arrows represent areas of E6/E7
positive nuclei. Representative images of each treatment group are shown for each target.
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Proliferative ability of the epithelial cells in each tumor was assessed by Ki67
expression (Fig 4.5C). Only cells in basal and intermediate layers of epithelium stained
positive for Ki67. Overall, cetuximab treated xenografts contained significantly fewer
Ki67 positive cells as compared to those in the control. However, when the number of
Ki67-positive nuclei was normalized to the total epithelial area in the section, the
difference in proliferating cells between the treatment groups was no longer significant
(Fig 4.5C).

The p16, p53, and Ki67 staining patterns in these tissues suggest

differentiation-dependent downregulation of viral oncogene expression.
To assess the spatial expression patterns of E6/E7 we used RNAscope (Advanced
Cell Diagnostics), a method of RNA in situ hybridization, in a selection of tissues from
each group. In the untreated group, expression of E6/E7 was only seen in the basal layers
of the differentiated epithelium, which correlates with high p16 and Ki67 expression, and
lack of p53 staining in these layers (Fig 4.5D). E6/E7 RNA positive nuclei were difficult
to detect in cetuximab treated groups, but were identified in cells in the basal layer albeit
with lower staining intensities (Fig 4.5D). These data indicate that concurrent with
increased differentiation, cetuximab treatment leads to lower expression of HPV
oncogenes in SCC47 xenografts. At present, we cannot determine if lower E6/E7 RNA
levels are the cause or result of increased differentiation in cetuximab-exposed tumors.
The reason for the discrepancy between our E6/E7 ISH and RT-qPCR data is not clear.
The method for RT-qPCR normalization may be at fault.
normalized to β-actin expression levels.

Our RT-qPCR data is

Since E6/E7 expression in vehicle treated

tumors is confined to the basal layers of epithelium, β-actin RNAs from the upper layers
of epithelium may dilute out the relative E6/E7 transcripts in the untreated tissues. This
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underscores the importance of evaluating targets by multiple methods and highlights one
of the limitations of using tumor homogenates to measure gene expression and protein
levels.
4.3.1C Effect of Trametinib Treatment on Viral Oncogene Expression in UMSCC47 Tumor Xenografts
Data from our laboratory has indicated that MEK1/2 is a critical factor for EGFRmediated regulation of viral transcript levels (described in Chapter 3). Therefore, we
hypothesized that directly targeting MEK1/2 in these tumors would have an antiviral
effect in SCC47 xenografts. To test this theory, we treated a cohort of animals bearing
SCC47 xenografts with 1mg/kg trametinib. The delay in tumor growth in the treatment
cohort was statistically significant as compared to the control group (Fig 4.6A). In
agreement with our hypothesis, trametinib treatment significantly blunted viral oncogene
transcript levels in xenografts (Fig 4.6B).

The levels of E6/E7 expression were only

moderately correlated with tumor growth (Fig 4.6C).
We quantified cFos and JunB RNA levels to determine if inhibition of MEK1/2
significantly altered their expression. Whereas we detected no change in the expression
of either AP-1 transcription factor when tumors were exposed to cetuximab, levels of
cFos and JunB RNA were significantly reduced in the trametinib treated tumors (Fig
4.15A). Additionally, there was a strong positive correlation between transcript levels of
cFos and JunB and E6/E7 RNAs (Fig 4.6B, C). Taken together, these results indicate
MEK inhibition effectively inhibits viral oncogene transcription in tumors from SCC47
cells. Furthermore, the strong correlation between levels of the AP-1 transcription factors
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cFos and JunB and viral oncogene RNAs may suggest MEK exerts its antiviral effect via
these transcription factors.

Figure 4.6 Trametinib produces antitumor effects concomitant with downregulation of viral
oncogene expression in SCC47 xenografts.
NSG mice bearing SCC47 xenografts implanted subcutaneously were given the MEK inhibitor trametinib
(1 mg/kg) or vehicle only (10% Cremophor EL, 10% PEG 400) daily by oral gavage. Tumors were
measured 3x/week by caliper and percent growth from treatment start (time=0) are shown in (A). RNA
from homogenized tumor sections was analyzed by RT-qPCR for expression levels of viral oncogenes E6
and E7, and AP-1 transcription factors cFos and JunB. Transcript levels were normalized to human β-actin
transcript levels. The average expression levels of normalized target from the vehicle tumors was set to 1
and data shown as fold-change compared to control. Relative expression levels of E6 and E7 are shown in
(B). Relative levels of E6 and E7 transcripts were plotted against the change in tumor volume over the
course of treatment and linear correlation assessed by Spearman’s r test (C). Relative expression levels of
cFos and JunB are shown in (D). Relative levels of E6 and E7 transcripts were plotted against the
expression levels of cFos (E) and JunB (F) and linear correlation assessed by Spearman’s r test. Error bars
= SEM, statistical significance assessed by Student t-test, *p≤0.05, **p≤0.01, ****p≤0.0001.

In summary, the SCC47 cell line produces moderately differentiated xenografts in
which EGFR/MEK signal inhibition produces antitumor and antiviral effects.
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A

summary of the data obtained from the SCC47-cetuximab cohort is shown in
Supplemental Table 1. While 1mg/kg dose of cetuximab had no inhibitory effect on
tumor growth, an increased dose of 5mg/kg significantly reduced tumor growth rate.
However, we observed no overall change in E6 or E7 RNA levels in tumor homogenates
from cetuximab treated animals at either dose when compared to controls. Levels of
cFos and JunB also remained unchanged in treated animals.

Cetuximab treatment

decreased total and phospho-EGFR and phospho-ERK1/2 levels in tumors as compared
to controls. In untreated tumors, high levels of p16 and Ki67 staining in the lower layers
of epithelium corresponded with areas of E6/E7 RNA expression. p53-positive cells in
these tumors were restricted to upper epithelial cell layers lacking E6/E7 RNA.
Cetuximab treatment induced differentiation as evidenced by fewer stratified layers of
epithelium and increased keratin deposits. There was no overall change in the number of
Ki67-positive cells/mm2 epithelium in response to cetuximab treatment indicating that the
remaining cells were capable of proliferating. In contrast to results from cetuximab
treated animals, administration of trametinib resulted in diminished tumor growth along
with significantly decreased E6 and E7 transcript levels, which were tightly correlated
with reduced levels of cFos and JunB RNA. Indicating that MEK inhibition is important
in controlling viral gene expression in tumors from this cell line.
4.3.2A Effect of Cetuximab Treatment on Viral Oncogene Expression in UMSCC104 Tumor Xenografts
The SCC104 cell line is derived from a recurrent HPV16-positive floor-of-mouth SCC
and contains 1 viral genome [156, 199]. The integrated viral genome contains one
breakpoint within the E2 ORF indicating that the LCR is maintained upstream of E6 and
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E7 genes [156]. This cell line was derived from a tumor that had been twice resected and
previously treated with chemotherapy and radiation [198]. Because of its aggressive
nature, cetuximab was used at a higher dose (5mg/kg, 3x/week) for xenografts derived
from this cell line. These tumors grew very rapidly and we were only able to treat the
animals for two weeks after tumors appeared before the control animals required
euthanasia. However, cetuximab treatment significantly inhibited the growth of SCC104
xenografts (Fig 4.7A). The erratic growth curves for the UM-SCC104 xenografts reflect
difficulty in measuring these tumors during growth using our previously determined
criteria (described in the methods section) (Fig 4.7A). At ~3 weeks post-implantation,
the tumors contracted in length and width and instead grew in height. As an additional
comparison, final weights of the UM-SCC104 tumors are shown (Fig 4.7B). Contrary to
our hypothesis, SCC104 xenografts responded to cetuximab treatment with heightened
E6 and E7 expression (Fig 4.7C). There was also a significant negative correlation
between E6/E7 levels normalized to β-actin and tumor growth in SCC104 xenografts (Fig
4.7D). These data suggest that the antitumor effects seen in this cohort are independent
of downregulated viral oncogene expression.
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Figure 4.7 Cetuximab downregulates tumor growth rate while producing increased E6 and E7
transcript levels in SCC104 xenografts.
NSG mice bearing SCC104 xenografts implanted subcutaneously were given cetuximab (5 mg/kg) or
vehicle only (0.9% saline) by i.p injection 3x/week. Tumors were measured 3x/week by caliper and
percent growth from treatment start (time=0) are shown in (A). Final tumor weights (in grams) at necropsy
are shown (B). RNA from homogenized tumor sections was analyzed by RT-qPCR for expression levels of
viral oncogenes E6 and E7, and AP-1 transcription factors cFos and JunB. Transcript levels were
normalized to human β-actin transcript levels. The average expression levels of normalized target from the
vehicle tumors was set to 1 and data shown as fold-change compared to control. Relative expression levels
of E6 and E7 are shown in (C). Relative levels of E6 and E7 transcripts were plotted against the change in
tumor volume over the course of treatment (D) or the final tumor volume (E) and linear correlation
assessed by Spearman’s r test. Relative expression levels of cFos and JunB are shown in (F). Relative
levels of E6 and E7 transcripts were plotted against the expression levels of cFos (G) and JunB (H) and
linear correlation assessed by Spearman’s r test. Error bars = SEM, Statistical significance assessed by
Student t-test, *p≤0.05, **p≤0.01, ***p≤0.001.

The levels of cFos were not significantly altered in cetuximab treated mice as
compared to vehicle-only controls and although JunB levels were slightly elevated, the
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average was not statistically significant (Fig 4.7F). There was no correlation between
cFos and viral oncogene transcript levels (Fig 4.7G). However, there was a moderate
positive correlation between JunB RNA and E6/E7 transcript levels (Fig 4.7H). It should
be noted that this cell line contains a deletion in NOTCH1 that results in a truncated
version of the protein [156]. Loss of function mutations in this gene are commonly
associated with HPV-positive cervical cancer and HNC and have been shown to
upregulate cFos expression [181, 184, 191, 204-208]. Conversely, exogenous expression
of functional NOTCH1 in HeLa cells led to decreased E6/E7 expression by reducing
cFos expression levels [191]. Therefore, the lack of antiviral response to cetuximab in
SCC104 tumors may be due to the lack of EGFR-mediated control of AP-1 TF
expression levels in this cell line.

14.3.2B UM-SCC104 Biomarker Detection by Histology and IHC
To further define the effects of EGFR inhibition on these xenografts we evaluated
sections of these tumors histologically. Sections prepared from FFPE blocks were stained
with H&E to first observe tissue morphology. Subsequent sections of the tumors were
stained by IHC for total EGFR, phospho-EGFR(Y1173), phospho-ERK1/2, p16INK4a,
human mitochondria maker, p53, and Ki-67. SCC104 xenografts from vehicle treated
mice were composed of poorly differentiated epithelium similar to the parental tumor as
reported by Tang, et al. [198]. These cells form cystic or lobular epithelial structures in
xenografts and tissues remained poorly differentiated even in the cetuximab treatment
group with little to no evidence of stratification or keratinization (Fig 4.8A). The main
morphological difference between tumor epithelium from cetuximab-treated mice as
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compared to controls, was the size of the epithelial lobules which stain darker than the
necrotic, stromal, or connective tissues also observed in the tumors (Fig 4.8A). Tumors
from the cetuximab-treated group contained small or mixed lobules of epithelium while
untreated tumors were composed of large lobules of epithelium. Cetuximab-treated mice
had tumors with a higher percentage of stroma compared to epithelium than was present
in the control groups (Fig 4.8B) but contained less total stromal area overall (average of
1.9mm2 versus 6.81mm2 for cetuximab and vehicle groups, respectively). Tumor
vascularization was observed in tumors from both treated and vehicle control mice (Fig.
4.8B). Necrotic areas were evident in both groups but composed a higher percentage of
the tumors in vehicle control than cetuximab-treated (Fig 4.8B). Tumors with larger
lobules (control group) contained areas of necrosis usually at the center of the lobule.
Conversely, the tumors composed of smaller epithelial lobules (cetuximab treated),
tended to have a single area of necrosis near the center of the tumor mass. Analysis of
tumor components by morphology (described in methods) revealed there was
significantly more necrosis, both as total area of necrosis and as a percentage of total
tumor area, in the tumors of vehicle-treated mice than in those of cetuximab-treated mice
(Fig 4.8B). The increased necrosis in tumors of vehicle-treated mice was likely due to
the large size of these tumors and consequent lack of an adequate blood supply.
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Figure 4.8 Cetuximab treatment induces morphologic changes in SCC104 xenografts.
FFPE sections of xenografts from cetuximab and control tumors were H&E stained, representative images
for vehicle and cetuximab sections are shown (A). Slides were scanned using an Aperio slide scanner and
percent tumor composition determined using HALO software. Results are summarized in (B).
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The IHC results shown in Figures 4.9-4.10 are summarized in Table 3. Cellular
staining for EGFR was diffuse in tumors from both treatment and control groups (Fig
4.9A). Levels of both total and phospho-EGFR were lower in cetuximab-treated tumors
than vehicle controls indicating the drug efficiently reached the tumors (Fig 4.9A and B).
Additionally, the intensity of phospho-ERK1/2 staining in tissues receiving EGFR
inhibitor was reduced consistent with the drug interrupting upstream signaling to this
pathway. Together, these data indicate that cetuximab was effective in inhibiting EGFR
signaling and blunting the activity of the downstream effector ERK1/2.

Table 4.3 IHC Scores for UM-SCC104 5mg/kg Cetuximab Cohort
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Figure 4.9 Cetuximab decreases levels of active EGFR and ERK1/2 in SCC104 xenografts.
FFPE sections from cetuximab treated and control tumors were stained by IHC for total EGFR (A),
phospho-EGFR(Y1173) (B), and phospho-ERK1/2 (C). Representative images of each treatment group are
shown for each target. Staining intensity was scored from 0-3, with 3 indicating the strongest signal.

As a surrogate marker of viral activity, we analyzed the levels of p16INK4a, which
is a well-documented marker of HPV-positive cancers [73-76]. The strength of p16
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staining was slightly but consistently lower in the tumors from the treatment group
compared to those in the control group (average intensity 2 vs 3, respectively) (Fig
4.10A). The decrease in p16 intensity in cetuximab-treated tumors is confounding since
RT-qPCR revealed elevated E6/E7 levels in cetuximab-treated tumors and suggests that
decreased p16 is independent of E7 levels.
Consistent with high levels of E6 expression, p53 was not detectable in either
cetuximab or untreated tumors (Fig 4.10B). Tang, et al. reported that the SCC104
parental tumor contained ~10% p53-positive cells and a subsequent 50% loss of p53positive cells was shown in cancer stem cell xenografts from this cell line [198]. This
suggests the possibility that successive passaging of this cell line has resulted in selection
of clones with lower p53 expression.
The total number of Ki-67-positive epithelial cells was significantly higher in
tumors from untreated mice than those receiving cetuximab (Fig 4.10C). However, when
the number of Ki-67-positive epithelial cells was normalized to epithelial area, the
difference between the two groups was no longer significant (Fig 4.10C, lower panel).
This indicates a possible selection for cells with higher proliferative capacity following
cetuximab treatment, which would agree with our finding of elevated viral oncogene
expression in these tumors (Fig 4.7B).
To gain spatial information about the expression of viral oncogene levels in these
tissues, we performed RNAscope (Advanced Cell Diagnostics), a method of RNA in situ
hybridization, for HPV E6/E7 (Fig. 4.10D). Staining was analyzed using HALO image
analysis software (Indica) and the percentage of E6/E7 positive nuclei determined by
dividing the number of positive nuclei by the total number of nuclei in each tissue
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section. Due to their larger epithelial area, the total number of E6/E7-positive cells was
slightly higher in tissues from the untreated group (Fig 4.10D). However, when the
number of E6/E7 expressing cells was normalized to total epithelial area, a higher
percentage of nuclei stained positive for E6/E7 RNA in tumors from the cetuximab
treated mice, which is consistent with the heightened expression of E6 and E7 measured
by RT-qPCR (Fig 4.7B).
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Figure 4.10 Cetuximab decreases p16 but not p53 or Ki-67 levels in SCC104 xenografts.
FFPE sections were stained by IHC for p16INK4a (A) and p53 (D07) (B) and staining intensity was scored
from 0-3, with 3 indicating the strongest signal and scores are summarized in graphs. (C) IHC for Ki67.
Slides were scanned using an Aperio slide scanner and staining analyzed using HALO software. Number
of total Ki6-positive cells for each tumor are shown in the top graph while number of Ki-67-positive cells
normalized to epithelial area for each tissue section is shown in the bottom graph. (D) RNA ISH was
performed to determine spatial expression of HPV E6 and E7. Representative images of each treatment
group are shown for each target.
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A data from the SCC104 xenografts is shown in Supplemental Table 2. Overall,
in SCC104 xenografts, cetuximab was effective in downregulating levels of phosphoEGFR and phospho-ERK1/2. Cetuximab treatment led to decreased tumor growth and
altered morphology. Epithelial lobules were smaller and necrosis was substantially
reduced from 47% to 4% by cetuximab treatment. Cetuximab did not lead to reduced cFos or JunB RNA levels in xenograft tumors (Fig 4.7D). The lack of change in c-Fos and
JunB levels may be due to the loss of functional Notch1 which normally inhibits
expression of these genes and likely explains why HPVE6 and E7 levels were not
diminished in response to cetuximab. Furthermore, the unchanged levels of p16, p53 and
Ki67 reflect the maintenance of high expression of E6 and E7 in the tumors.

4.4 Discussion
HPV-positive HNSCC represents an increasing percentage of total cases of HNSCC
(~30% of all HNSCC world-wide in 2014) [87, 88, 179]. While the prognosis for these
HPV-positive patients is favorable, the current treatment modalities have high morbidity
[154]. The current standard of care for HNSCC is the same regardless of HPV status,
although there are clinical trials underway to determine the benefit of de-escalation of
treatments. A more thorough understanding of the effects of current therapies on the
viral oncogenes presumed to be driving these cancers will provide a basis for designing
more effective therapies.
Cetuximab, a monoclonal antibody that inhibits EGFR activity is currently used in
the treatment of both HPV-negative and HPV-positive HNSCC. As shown in chapter 3,
HPV oncogene expression can be inhibited by EGFR inhibition. Previous studies have
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shown that cetuximab can inhibit growth of HPV-positive xenografts [166, 193, 209].
However, the effect of cetuximab treatment on viral activities in these xenografts had not
been investigated. Pogorzelski et al. evaluated the role of E6 and E7 in modulating the
response of cells to cetuximab however this was done in HPV-negative cell lines
transduced with E6 and E7. Therefore, the LCR elements which control normal viral
transcription were not intact [210]. Here, we asked if EGFR inhibition in vivo produced
antiviral effects including decreased viral oncogene expression levels, reinstatement of
p53 expression, and diminished p16 levels indicative of restored pRb. We evaluated
xenografts from two HPV-positive HNSCC cell lines thought to represent the two HPVpositive HNSCC subtypes, “classical” (CL) and “inflamed/mesenchymal” (IMS) [207]
(data from these xenograft cohorts is summarized in Appendix B - Supplemental Tables 1
and 2). We also assessed the response of viral transcription to cetuximab treatment in
xenografts from two HPV-positive cervical cancer cell lines (See supplemental data in
Appendix B sections B.1 and B.2), one maintaining an intact LCR and the other lacking
the viral control region upstream of integrated E6 and E7 [156]. In our study, cetuximab
appears to suppress tumoriginicity through two different mechanisms: either in
conjunction with or independent of antiviral effects. Our results show that EGFR and
MEK1/2 inhibition has antitumor effects in xenografts from HPV-positive cancer cell
lines. We observed decreased E6 and E7 RNA expression levels in two of the xenograft
groups upon EGFR or MEK1/2 inhibition, and downregulation of viral oncogene
expression appeared to correlate with the ability of the drug to reduce expression of AP-1
transcription factors, cFos and JunB.
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In our study, cetuximab treatment reduced growth rate in xenografts from HPVpositive HNSCC cell lines (Figs. 4.2A and 3A) as well as HPV-positive cervical cancer
cell lines (Supplemental Figs. 4A and 5A), however a higher dose of cetuximab was
required to obtain an antitumor effect in the former group indicating possible moderate
resistance to the drug. While EGFR inhibition downregulated viral oncogene levels as
measured in tumor homogenates from SiHa xenografts (Supplemental Fig. 4B), E6 and
E7 levels in SCC47 xenografts remained unchanged (Fig. 4.2B). However, the results
from the SCC47 xenografts are misleading. Analysis of spatial expression of E6 and E7
by RNA ISH in SCC47 tumors revealed that these viral oncogenes are expressed
differentially in the stratified epithelium of these tumors with the highest concentration of
E6/E7 expression confined to the basal layers of epithelium (Fig. 4.5D). It is important to
note that, for RT-qPCR, oncogene transcript levels were measured in a homogenized
tissue sample and normalized to total levels of human β-actin transcripts, which are
expressed throughout the epidermal layers, resulting in dilution of the E6 and E7
transcript levels. Growth of the cervical cancer cell line, W12E, in the organotypic raft
system, which allows differentiation of epithelium reveals a similar pattern of viral
oncogene expression, with E6 and E7 expressed in the basal cells and disappearance of
detectable levels in the suprabasal layers [202, 203]. This suggests that the decreased
E6/E7 levels might be mediated by cetuximab-induced differentiation in these tumors and
not direct effects on viral transcription.
SCC47 is thought to represent the CL subtype of HPV-positive HNSCC described
by Keck et al. [207].

The CL HPV-positive tumors are typically moderately

differentiated and highly proliferative as compared to the IMS type.
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Prognosis for

patients with the CL type of tumor is also poorer than for the IMS type. To gain an idea
of the effects of cetuximab treatment in this tumor type, we evaluated SCC47 tumors
histologically. Cetuximab-mediated downregulation of total and phospho-EGFR was
evident (Table 4.2 and Fig. 4.4A, B) as was decreased staining for phospho-ERK1/2
(Table 4.2 and Fig. 4.4C) indicating that cetuximab treatment inhibited EGFR activation
and reduced downstream signaling through MEK. In agreement with data from Vermeer
et al. showing sustained ERK1/2 activation following incubation with cetuximab and
trastuzimab in vitro, levels of ERK1/2 activity were not completely diminished in SCC47
xenografts following cetuximab treatment [201]. The presence of Ki67-positive cells in
these tumors (Fig. 4.4C) suggests that the remaining ERK activity is sufficient to sustain
some tumorigenic activity. This indicates that there is possibly upregulation of other
cellular pathways resulting in MEK/ERK activation.

A recent publication reported

enhanced expression of HER2 and HER3 in HPV-positive HNSCC and it thought to
contribute to cetuximab resistance [211]. Levels of Her2/Her3 have not been reported for
SCC47 cell line but if upregulation is present, it may contribute the remaining ERK
activity observed. Together with the antiviral effects seen in SCC47 xenografts treated
with the MEK inhibitor, trametinib, these data indicate that MEK inhibitors may have
therapeutic value in HPV-positive HNSCC.
Restoration of functional p53 levels and thus cell cycle control is a goal in the
treatment of HPV-positive cancers. TP53 is mutated in many cancers (reviewed in
[212]). However, presumably due to E6-mediated degradation of the p53 protein, HPVpositive cancers typically maintain wild type TP53 [182, 184].

Previous studies have

shown that suppression of E6 and E7 levels in HPV-positive cancer cell lines by siRNA
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has anti-tumorigenic effects [77-80]. These studies additionally report restoration of p53
levels and induction of apoptosis. In the SCC47 xenografts, p53 expression was seen in
the suprabasal layers of epithelium and coincided with downregulation of E6 and E7
expression (Fig. 4.5B and Table 4.2).

Cetuximab treatment resulted in cellular

differentiation concurrent with downregulation of E6 and E7 expression and recovery of
p53. These data indicate that induction of epithelial differentiation in the CL HPVpositive tumor type through use of EGFR or downstream inhibitors may have therapeutic
effects.
HPV-positive cancers typically express elevated p16 due to E7-mediated
inactivation of pRb [73, 74]. We questioned if changes in viral oncogene expression
would result in altered p16 expression as a surrogate readout of viral activity. Levels of
p16, as detected by IHC, were markedly lower in cetuximab treated SCC47 tumors (Fig.
4.5C) and coincided with areas of decreased E6/E7 expression measured by RNA ISH
(Fig. 4.5D) indicating that the reduction in viral gene expression correlates to lower viral
oncoprotein levels. This is another indication of the antiviral effects of EGFR pathway
inhibition in these tumors. The presence of remaining albeit diminished p16 and p53
levels following cetuximab treatment may indicate that low levels of E6 and E7 are still
expressed in these cells. Further studies are needed to determine whether the cetuximabassociated reduction in viral oncoprotein levels in SCC47 xenografts is enough to
increase sensitivity of these tumors to radiotherapy.
Histological evaluation of SCC47 xenografts from cetuximab and control groups
revealed numerous morphological differences. Cetuximab treated tumors were smaller
and therefore contained a smaller area of SCC and infiltrating stroma (Fig. 4.3A). Ki67
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staining was markedly lower overall in cetuximab treated tumors (Fig. 4.3C, upper
panel). However, when normalized to the area of epithelium in each section, the number
of Ki67 positive cells was not significantly different (Fig. 4.3C, lower panel) indicating
that decreased proliferative ability in the remaining cells could not account for
differences in tumor size. SCC47 xenografts from cetuximab treated animals contained
very little epithelia and the majority of the tumor was composed of stroma and keratin
deposits indicating a strong inhibition of cellular proliferation and induction of
differentiation. The members of the AP-1 transcription factor family are involved in
epithelial differentiation and expression levels change concurrent with differentiation.
No difference was observed for cFos or JunB levels in tumor homogenates, similar to
what was seen with E6 and E7 (Figs. 4.2D and B).

It is likely that we would also

observe a similar change in expression patterns concurrent with cellular differentiation if
c-Fos and JunB transcripts were measured by RNA ISH in these tumors. Taken together,
it is clear that cellular differentiation and HPV oncogene expression are tightly linked in
SCC47 xenografts. Whether the cetuximab-mediated cellular differentiation is preceded
by a decrease in E6 and E7 levels or the cause of E6 and E7 downregulation is still
unclear and may be difficult to tease out in this system.
In contrast to cetuximab treatment, administration of trametinib to animals
bearing SCC47 xenografts resulted in significantly decreased levels of viral oncogene
expression levels concomitant with cFos and JunB downregulation (Fig. 4.4A). Both
SiHa-cetuximab and SCC47-trametinib xenografts exhibited strong correlation between
E6/E7 expression levels and levels of cFos, indicating that these transcription factors
might play an important role in facilitating the antiviral response observed (Fig. 4.4D-F
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and Supplemental Fig. 4D-F). Histological comparison of SCC47-trametinib treated
tumors with those treated with cetuximab will hopefully provide deeper insight into the
mechanisms at play.
Cetuximab clearly exhibited antitumor effects independent of antiviral effects in
SCC104 and CaSki xenografts. Despite significant suppression of tumor growth, viral
oncogene RNA levels were elevated or remained unchanged in SCC104 and CaSki
xenografts treated with cetuximab (Fig. 4.7A and Supplemental Fig. 5A). The increase in
viral oncogene expression levels following cetuximab treatment might be attributed to
two different mechanisms.

It is possible that EGFR inhibition induced elevated

expression of viral oncogenes in these tumors through activation of the promoter
controlling transcription of E6 and E7. However, it is also plausible that EGFR inhibition
instead created a selective pressure, which led to clonal growth of a cellular population
with higher oncogene expression levels. CaSki cells contain only one transcriptionally
active viral genome. This integrant lacks a portion of the LCR upstream of E6 and E7 in
this active integrant and it is unclear what drives expression of these genes in this cell
line. Preliminary data from our lab indicate upregulation of E6 and E7 expression
without apparent selective clonal expansion in CaSki cells in vitro following only 48
hours treatment with cetuximab.

This supports the idea that EGFR inhibition is

facilitating upregulation of expression in the overall population of cells. Further analysis
of transcriptional control of viral gene expression in CaSki cells may shed light on our
results and help to understand the mechanism underlying viral oncogene upregulation
following cetuximab treatment.
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The other explanation for the increase in E6 and E7 transcript levels after
cetuximab administration is selection for a subpopulation of cetuximab resistant cells that
already express high levels of E6 and E7. SCC104 cells were originally described as a
mixed population of cells containing a small subset of cancer stem cells (CSS) exhibiting
high ALDH expression (2.32% of the total cell population) [198]. Tang et al. implanted
NSG mice with SCC104 subpopulations expressing either high or low ALDH levels and
only the CSS were able to produce tumors.

However, the tumorigenicity of the

remaining cells that comprised the majority of the original population and expressed
moderate levels of ALDH, was not evaluated. It is unknown if the percentage of each
cell group has changed after multiple rounds of culturing in vitro. In our study, cells
were not sorted prior to implantation therefore the effects of cetuximab treatment on
these distinct subsets of cells, if still present in the implanted population, are not known.
Future studies could address the presence and proportion of each of the ALDH subsets in
our SCC104 cell stocks and investigate whether these proportions change following
xenograft development and cetuximab treatment and if E6 and E7 expression differs or
remains similar among these groups. Interestingly, RNA ISH staining of tissues from
these populations indicates that a higher percentage of cells from cetuximab treated
SCC104 tumors stained strongly for E6/E7 expression than in the vehicle treated group
(Fig. 4.10D). These data support the idea that cetuximab treatment selected for a subset
of cells with strong viral oncogene expression in SCC104 xenografts.
Decreased E6/E7 RNA levels were not observed in CaSki, SCC104, or SCC47
xenograft homogenates by RT-qPCR following cetuximab treatment. Neither was there
apparent downregulation of cFos or JunB expression in these tumors (Fig. 4.2A, 4.7A
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and Supplemental Fig. 5A). Whether the failure of cetuximab to downregulate AP-1
contributed to the unchanged E6 and E7 levels in CaSki cells is unclear. As discussed
earlier, the levels of cFos and JunB RNA as measured by RT-qPCR in SCC47 xenografts
may not be representative of the true expression of these genes if they are expressed only
in distinct layers of differentiated epidermal tissue. Additional methods including IHC
and RNA ISH could be used to validate RT-qPCR results in the context of epithelial
morphology and differentiation state.

The fact that trametinib treatment induced

significantly decreased E6, E7 and AP-1 RNA levels in SCC47 xenografts indicates that
cFos and/or JunB may facilitate the antiviral effects in this cell line. As mentioned
previously, SCC104 cells have a mutation in NOTCH1 resulting in a truncated form of
the protein [156]. In an exome sequencing study of 32 primary HNSCC tumors,
NOTCH1 mutations were seen in 15% of tumors analyzed including three out of four
HPV-positive tumors [154, 184].

NOTCH1 mutations have also been seen in a

percentage of HPV-positive cervical cancers and are associated with elevated expression
levels of AP-1 transcription factors, including cFos and JunB [126, 191]. Reintroduction
of functional Notch1 was shown to decrease levels of AP-1 transcription factors
concomitantly with a reduction in E6/E7 expression levels [191]. Whether inhibitors
targeting another cellular pathway would be effective in changing AP-1 components in
this cell line is unclear. Further assessment of the promoters controlling viral oncogene
expression, whether they are cellular or viral, may provide insight and aid in determining
effective means of downregulating E6 and E7 expression.
SCC104 cells are reported to express high levels of EGFR; therefore, the
antitumor effects may be mediated via the high EGFR expression in this cell line.

108

Cetuximab-mediated downregulation of total and phospho-EGFR as well as phosphoERK1/2 was apparent (Table 4.3 and Figs. 4.8B and C). The downregulation of these
proteins indicates that cetuximab treatment successfully inhibited EGFR/MEK signaling.
In SCC104 tumors, we were unable to detect p53, even in the cetuximab treated group
(Fig. 4.10B). Low levels of p53 staining were seen even in the parental tumor [198].
The lack of detectable p53 in these tumors makes sense due to the relatively high levels
of E6/E7 expression seen in this cell line [199]. Furthermore the lack of p53 recovery in
tumors that received cetuximab corresponds to the upregulation in viral oncogene
expression levels observed (Fig. 4.7B).

While cetuximab-treated SCC104 tumors

exhibited slightly less intense staining for p16, expression was still strong and diffuse in
these tissues (Fig. 4.10A). The persistence of p16 and absence of p53 (Fig. 4.10B)
supports the lack of E6/E7 downregulation seen by RT-qPCR (Fig. 4.7B) and RNA ISH
(Fig. 4.10D).
Histological evaluation of SCC104 xenografts from cetuximab and control groups
revealed smaller tumors and therefore contained a smaller area of SCC and infiltrating
stroma (Fig. 4.8A). As in SCC47 tumors, cetuximab induced markedly lower overall
Ki67 levels in SCC104 xenografts but this difference disappeared when the number of
Ki67 cells was normalized to epithelial area (Fig. 4.10C). Therefore, decreased
proliferative ability in the remaining cells could not account for differences in tumor size.
Cetuximab treated SCC104 tumors exhibited a higher ratio of epithelium to
stroma, indicating inhibition of fibroblast recruitment (Fig. 4.7B). However, it should be
noted that fibroblasts present in the cetuximab treated tumors from both cell lines
exhibited less staining for SMA, a marker of activated cancer associated fibroblasts
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(CAFs) (Supplemental Fig. 3A and B). CAFs have been reported to have multiple roles
in promoting malignant progression including enhancing metastatic potential.
Recruitment and activation of CAFs by cancer cells is thought to take place via paracrine
signaling and the TGF-β family of molecules, among others, has been shown to be
important (Reviewed in [213]). The decreased SMA staining in cetuximab treated tumors
indicates that EGFR inhibition downregulated release of fibroblast recruitment and/or
activation signals from the cancer cells.
It is interesting to note that SCC47s contain 47 integrated copies of the HPV16
genome whereas SCC104 cells harbor only 1 viral genome copy as measured by whole
genome sequencing [156].

Likewise, CaSki cell lines have 831 genome copies as

compared to 1.5 in SiHa. The viral LCR seems to be retained in the majority of the
integrated genomes, including all of the viral integration sites in the cells harboring low
viral genome numbers [156]. As CaSki and SCC104 both exhibited heightened viral
oncogene expression following cetuximab administration, the susceptibility of the virus
to EGFR inhibition is not solely based on the number of viral genomes present. Instead,
downregulation of viral oncogene transcription seems to correlate with the ability of
cetuximab to reduce cFos expression levels as discussed previously.
In HPV-associated cancers, understanding the role of EGFR in maintaining viral
oncoprotein levels may help to design more effective treatments and refine current
treatment protocols.

Cetuximab is already used in the treatment of HNSCC in

conjunction with chemotherapy/radiation and some benefit has been shown for patients
with advanced stage HPV-positive cancers over HPV-negative [172, 173]. However,
previous clinical trials using cisplatin plus cetuximab or cetuximab as a monotherapy in
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cervical cancer have failed to show a therapeutic benefit for the use of EGFR inhibitors in
their patient populations [174, 175]. Based on our results, we suggest that cetuximab is
able to induce antiviral effects in a subset of HPV-positive cancers. However, the extent
and importance of this effect in the clinical setting remains to be studied. Retrospective
studies examining tumor differences including expression levels of viral oncogenes and
genome integration status, NOTCH1 status, c-Fos activity, and EGFR-signaling
components between patients who had a favorable response to treatment may help to
shed additional light and identify patient populations which might benefit from these
therapies.

4.5 Limitations of This Study
Our study presents novel information regarding the mechanism of antitumor effects of
cetuximab in HPV-positive cancers, however questions still remain.

In the SCC47

xenografts, it is yet unclear whether cetuximab-induced differentiation is the effect or
cause of viral oncoprotein downregulation. As discussed, histological evaluation of
trametinib treated SCC47 tumors may shed some light on this question. Additionally, the
small number of animals in each treatment group may present a concern as the sample
sizes prohibit robust statistical analysis. Repetition of this study for a selection of the cell
lines and treatments with larger cohort sizes may be necessary to increase statistical
power and demonstrate reproducibility. In this study, we have attempted to utilize cell
lines representing a range of HPV-positive cancers, however, this has made defining a
mechanism of action difficult due to the differences and complexities of each cell line.
Further analysis of multiple cell line as well as patient derived tumor xenografts for each
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of the HNSCC HPV-positive cancer subtypes will be necessary to define the molecular
mechanisms whereby cetuximab exerts antitumor effects in HPV-positive cancers.
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Chapter 5 - Discussion and Future Directions
This study provides insight into the ability of EGFR signaling to influence HPV
oncogene transcription both in preneoplasia as well as in a model of HPV-positive
cancer.

Transformation of cells by HPV has been reported to provide growth factor

independence. The mechanisms by which this takes place have been studied using
exogenous overexpression of viral proteins.

Numerous studies have shown that

expression of one or more HPV oncoproteins can increase EGFR levels and signaling
potential [63-66, 72, 121-124]. In this work, we sought to define the extent of HPVassociated dysregulation of EGFR signaling and determine if EGFR signaling affected
HPV early transcription in a model of preneoplasia. We also sought to determine if
EGFR-associated control of viral transcription extended to HPV-positive cancer cell
lines, wherein inhibitors could downregulate viral oncogene transcription in a xenograft
model of HPV-positive cancer.
Inhibition of EGFR/MEK signaling led to antiviral effects in NIKS-SG3 including
downregulated viral oncogene transcription and reduced viral genome burden in infected
cells. NIKS-SG3 treated with cetuximab also exhibited increased sensitivity to apoptotic
stimuli. In xenografts, antitumor effects of cetuximab occurred either concurrent with or
independent of changes in viral oncogene expression, depending on the tumor line.
EGFR/MEK downregulation of viral RNA levels was strongly correlated with the ability
of the inhibitor to decrease levels of the AP-1 transcription factors cFos and JunB,
suggesting that these proteins may play a role in mediating the effects of these inhibitors
on viral oncogene expression.
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We determined that EGFR signaling modulates HPV oncogene transcription in
cells carrying episomal viral genomes and that these cells are still sensitive to
EGFR/MEK inhibitors. EGFR activation of NIKS-SG3 cells produced heightened viral
oncogene expression and increased protein levels of the HPV-associated biomarker p16.
These results suggest that E7 protein levels were heightened concomitant with RNA
transcripts.

Conversely, inhibition of EGFR or MEK resulted in decreased viral

transcript levels. Furthermore, the antiviral effects of EGFR/MEK inhibitors extended to
decreased viral genome burden and increased sensitivity to DNA damage in treated cells.
Together, this data suggests that the EGFR pathway is a therapeutic target for HPV
infections. It also provides a possible mechanism to explain the therapeutic effects of
EGFR inhibitors such as erlotinib on laryngeal papillomas in RRP [169-171]. This has
implications for the treatment of numerous HPV-associated diseases, including cancer,
cervical preneoplasias, RRP, and genital and cutaneous warts.
Evaluation HPV oncogene expression on EGFR pathway regulation in a model of
preneoplasia yielded surprising results. Contrary to previous reports, we discovered that
EGFR expression was slightly lower in HPV-positive NIKS-SG3 than their parental cell
line. The activation level of the EGFR pathway was not significantly enhanced by HPV
infection, as we did not detect reproducible upregulation of phospho-EGFR in
unstimulated cells. NIKS-SG3 are stably transfected with wild-type HPV16 genomes that
are maintained episomally. These cells are capable of recapitulating the viral lifecycle
and producing late viral proteins when grown in the organotypic raft system.
Furthermore, NIKS-SG3 cells are reported to exhibit growth factor independence,
indicating viral dysregulation of growth factor signaling pathways [135]. In agreement
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with this, we observed that viral infection did contribute a degree of resistance to
EGFR/MEK inhibition as seen by sustained viability in the presence of inhibitors.
Indicating that viral activities did alter dependence on this pathway but the effect was
subtle and differences in activation levels were not detectable in our system.
We also discovered that viral proteins did not significantly alter p53 levels in
NIKS-SG3 when grown in subconfluent monolayers.

This hindered our ability to

evaluate the cellular effects of viral transcriptional downregulation. It should be noted
that a previous publication by colleagues using a similar cell line, reported enhanced viral
oncogene expression and activity when cells were grown to confluence [176]. For the
most biologically relevant model available, our results should be confirmed in the
organotypic raft culture system, which would allow recapitulation of epithelial
differentiation and enable analysis of the effect of EGFR activation and inhibition on the
full viral lifecycle. One drawback of this model is that cells cannot be continuously
treated with EGF in the raft system as it prohibits cellular differentiation. It would be
possible, however, to grow epidermal equivalents and allow them to differentiate prior to
addition of EGF. This would enable investigation of the effect of EGF stimulation in an
active infection.

Our study further reinforces the importance of studying viral-host

protein interactions under the most biologically relevant conditions possible.
EGFR activation-induced upregulation of viral transcription has many
implications in HPV disease and progression to cancer. Numerous cofactors have been
implicated in the progression from HPV infection to malignancy. These include lifetime
number of sexual partners, parity, coinfection with other STIs, tobacco use, and longterm oral contraceptive use [89, 214-218]. Many of these cofactors possess the ability to
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induce inflammation and activation of growth factor signaling pathways.

Cervical

malignancies typically arise from cells of the transformation zone, an area of metaplastic
epithelium at the interface between the endo- and ectocervix [51, 86, 219]. The extensive
remodeling of cervical tissue that occurs during pregnancy may result in heightened
growth factor expression, increasing viral oncogene expression levels and exacerbating
the chance of cellular transformation [220]. This may partially explain why women with
high parity are at a higher risk of developing cervical cancer.
Chronic inflammation is considered a risk factor in cancer development [221] and
STIs have been shown to initiate an inflammatory response in the genital tract.
Coinfection with other STI’s including C. gonorrhea and HSV-2 has been shown to
increase the risk of HPV-associated cancer, possibly by stimulating inflammation [89,
218]. However, inflammatory causes do not have to be infectious. In fact, exposure to
seminal fluid itself has been implicated in activating release of inflammatory cytokines
from immortalized ectocervical cells in vitro [222]. While some studies have shown that
inflammatory cytokines can inhibit HPV gene expression in vitro, this seems to be
context dependent and this has not been examined in vivo [36, 223, 224]. Additionally,
we previously showed that nitric oxide or mainstream (MS) tobacco smoke exposure led
to heightened HPV oncogene expression, DNA damage and mutation rates in HPVpositive cancer cells in vitro [137, 225]. Alam, et al, also reported that exposure to
benzo[a]pyrene, a major component of MS tobacco smoke, activated the MEK pathway
and enhanced HPV oncogene expression and virion production in vitro [226]. Further
investigation into the effects of these factors on the tissue milieu may provide insight into
the mechanisms that underlie progression to cancer in HPV infected cells.
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In our xenograft model, cetuximab inhibited tumor growth either concurrent with
or independent of changes in viral RNA levels.

Viral oncogene expression was

downregulated in SiHa xenografts treated with cetuximab. However, administration of
cetuximab in animals bearing SCC104 or CaSki xenografts resulted in higher E6 and E7
RNA levels. It is unclear whether EGFR inhibition in these tumors upregulated viral
transcription or selected for a subpopulation of cells with heightened oncogene
expression. Interestingly, trametinib but not cetuximab was able to induce significant
downregulation of viral oncogene levels in SCC47. In all cell lines, downregulation of
cFos and JunB by EGFR/MEK inhibition was seen concomitantly with decreased E6 and
E7 levels. Whether this relationship is causative has yet to be determined.
The UM-SCC47 xenografts represent an interesting subset of HPV-positive
cancers. Untreated tumors from this cell line were moderately differentiated and RNA
ISH revealed downregulation of viral transcript levels in suprabasal layers.

This

indicates that differentiation events are tied to viral transcription, similar to a natural
productive infection. In the upper layers of epithelium from untreated SCC47 tumors,
downregulation of E6/E7 transcript levels and proliferative activity, as seen by Ki67
staining, corresponded with increased levels of nuclear p53. Cetuximab treatment further
enhanced differentiation in SCC47 xenografts, resulting in tumors containing very little
epithelium. The epithelial cells that remained following cetuximab treatment contained
comparatively low levels of E6/E7 expression, as visualized by RNA ISH, when
compared to basal cells in the untreated tumors. Downregulation of viral RNA levels
was seen concomitant with cellular differentiation; however, it is unclear whether the
decreased viral transcription is the cause or effect of cellular differentiation. Future work
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should investigate the fate of these remaining cells following exposure to
radiochemotherapy.

Cetuximab treatment and differentiation may have sensitizing

effects on these cells resulting in apoptosis. Conversely, the cetuximab resistant cells
could represent a population of cancer cells with prior resistance to cetuximab or cells
with acquired resistance, either of which are more resistant to therapy. Determining the
fate of these remaining cells following radiochemotherapy may provide insight into the
development of resistance to EGFR inhibitors.
The ability of trametinib to significantly inhibit viral transcription in SCC47 cells
while cetuximab did not suggests that the MEK/ERK pathway may not be sufficiently
inhibited by cetuximab. A previous report indicated that SCC47 cells sustained ERK
activation in the presence of cetuximab or trametinib in vitro [201]. Our cetuximab
tissues showed downregulated but not abolished ERK signaling suggesting possible
activation of this signaling node by another pathway.

Investigation of the histological

features of these tumors and comparison with cetuximab treated tumors may shed some
light on the different effects seen by these two inhibitors.
The UM-SCC104 cell line, which responded to cetuximab with upregulated HPV
oncogene transcript levels in the xenograft system, contains a NOTCH1 mutation. This
mutation is commonly seen in cervical cancers and is also seen in 14-15% of HNSCC
[154, 184, 207]. While Notch1 appears to play a beneficial role in the early stages of the
HPV lifecycle, by initiating cellular differentiation, loss of this protein appears to support
progression to malignancy [191, 208, 227]. Additionally, loss of Notch1 is associated
with upregulation of cFos expression [126, 191, 208]. In each of our xenograft lines, the
ability of the treatment to downregulate levels of cFos in the tumor appeared to
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correspond to downregulation of E6/E7 expression. Whether mutations in Notch1 affect
the response to EGFR inhibition should be further investigated. Possible dysregulation of
this and other associated pathways should be considered when determining the efficacy
of EGFR/MEK inhibitor therapy in HPV-positive tumors.
Our study revealed that EGFR/MEK inhibition produced antiviral effects by
downregulating E6/E7 expression in subsets of HPV-positive xenografts.

However,

further studies will need to be conducted to determine what viral oncoprotein
downregulation ultimately means in terms of treatment benefit. Cetuximab was able to
reduce growth of all of our xenograft lines, regardless of viral response.

Whether

downregulation of viral protein levels in the responding tumors results in heightened
sensitivity to chemoradiotherapy has yet to be determined. While numerous cancers
contain mutated p53, HPV-associated cancers typically do not. Reinstatement of p53
levels by decreasing E6/E7 expression should sensitize tumors to chemoradiotherapy and
numerous groups have shown this in vitro [79, 209, 228, 229]. This remains to be studied
in the clinic.

In fact, our lab is involved in a new clinical trial to determine if

administration of cetuximab as a neoadjuvant prior to chemotherapy or radiation
downregulates E6/E7 expression and increases radiosensitivity in HPV-positive HNSCC.
Data from this study will help to further understand the extent of EGFR-mediated control
of HPV oncogene expression in vivo.
EGFR or MEK1/2 inhibition resulted in decreased E6 and E7 RNA levels in SiHa
and SCC47 xenografts indicating that viral transcription can be modulated by EGFRpathway signaling. However, we did not investigate whether EGFR activation increased
viral oncoprotein levels in this system. Cisplatin, a platinum-based chemotherapeutic
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commonly used in the treatment of HPV-associated cancers, has been reported to activate
EGFR [162]. The effect of cisplatin-induced EGFR activation on viral activities and how
this might affect treatment outcome has yet to be investigated. However, this could have
significant implications in response to therapy and should be studied further.
Previously, HNSCC were classified based solely on anatomic site, stage, and
HPV-status.

However, a recent study analyzed gene expression profiles from an

extensive panel of HNSCC patient tumors including 44% HPV-positive tumors. The
authors discovered three distinct gene expression profiles which, when HPV-status is
factored in, creates five subtypes of HNSCC [207]. The authors argue that there are two
subsets of HPV-positive HNSCC, a classical type (CL) and an inflamed/mesenchymal
(IMS) subset.

CL HPV-positive HNSCCs contain upregulation of the polyamine

degradation pathway, which is correlated with high levels of cell proliferation. These
tumors also contain many of the copy number variations and mutations associated with
HPV-positive HNSCC including PIK3CA. Interestingly, over 40% of the CL HPVpositive tumors studied were keratinizing, indicating a higher degree of differentiation.
The phenotypic characteristics of these tumors are similar to the SCC47 xenografts.
SCC47 tumors have a rapid growth rate, are moderately differentiated, and tumors
contain keratin deposits indicating this cell line might be representative of the CL HPVpositive HNSCC subtype. Better understanding of the mechanism behind the cetuximabassociated differentiation in SCC47 xenografts and resulting reaction of these tumors to
chemoradiotherapy may help to inform whether these patients are good candidates for
EGFR/MEK inhibitors.
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In contrast to HPV-positive CL tumors, HPV-positive IMS tumors express more
mesenchymal markers, including vimentin and matrix metalloproteinases, while
expression of epithelial markers, including cadherins and cytokeratins, is downregulated.
Expectedly, these tumors appear poorly differentiated morphologically. IMS tumors also
exhibited heightened expression of immune response genes including CD8, indicating
immune involvement. Follow-up studies revealed the presence of infiltrating CD8+
lymphocytes in tumor sections. Interestingly, these patients had a higher 5-year overall
survival than the CL HPV-positive subgroup possibly owing to immune response.
Cetuximab’s therapeutic effects are hypothesized to partially depend on an effective
immune response [120]. It would be interesting to determine if these patients have a
better response to cetuximab therapy than those with CL HPV-positive tumors. The
delineations set forth by Keck, et al. are crucial in designing effective therapeutic
interventions that will best target each subtype. Additional research into how these
distinct subsets respond to individual therapies is needed.
As the single most prevalent sexually transmitted infectious agent, human
papillomaviruses present a significant health problem.

Cancers attributed to HPV

infection represent 5% of all cancers worldwide [5]. In addition to the well-established
relationship between high-risk HPVs and cervical cancer, infection with these viruses is
now associated with a growing number of head and neck cancers [5-7]. While the
greatest burden of cervical cancer falls on the developing world, the highest number of
incident cases of HPV-positive HNSCC is found in developed countries including the
U.S.
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There are effective vaccines that protect against the HPV types that cause 70% of
all cervical cancer and 90% of all HPV-associated head and neck cancers. However,
overall public health benefit is hindered by low uptake. In the U.S., currently only 40%
of females and <30% of males of the target age have received the full three dose series of
the vaccine [8]. Furthermore, the high cost of the vaccine limits its usage in developing
countries where it would be most beneficial in preventing cervical cancer. Although the
PAP screening program has been very successful in decreasing the incidence of cervical
cancer in the U.S. and other developed countries, there is no mechanism in place for
screening of women in developing countries. Furthermore, there is currently no clinically
available method of screening for oral HPV infections. Therefore continued research into
mechanisms that underlie HPV-associated malignant progression is imperative.
The growing number of HPV-positive HNSCC creates a new patient population
that will benefit from enhanced therapeutic approaches. Understanding of the pathways
regulating viral oncogene expression is imperative in designing effective therapies.
While this work focused on HPV16, mechanisms of viral transcriptional control are
similar for other oncogenic HPV types that have been studied [20]. The work herein
described the antiviral effects of EGFR/MEK inhibitors on HPV-positive cells both in
vitro and in vivo and sets the stage for future work to determine if the downregulation of
viral activities translates to increased sensitivity to chemoradiotherapy. Results of these
studies may help to design more effective treatments and refine current treatment
protocols for HPV-associated diseases.
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Appendix A – Abbreviations
DMEM – Dulbecco’s modified eagle medium
DMSO – dimethylsufoxide
dsDNA – double stranded DNA
EGF – epidermal growth factor
EGFR – epidermal growth factor receptor
ERK1/2 – extracellular signal-regulated kinase-1/2
HPV – human papillomavirus
HNC – head and neck cancer
HNSCC – head and neck squamous cell carcinoma
IB – immunoblot
IHC – immunohistochemistry
LCR – long control region
MAPK – mitogen-activiated protein kinase
MEK1/2 – mitogen-activated protein kinase kinase-1/2
NBF – neutral buffered formalin
NSG – NOD/SCID-gamma
OPSCC – oropharyngegal squamous cell carcinoma
PBS – phosphate buffered saline
PI3K – phosphoinositide 3‐kinase
RT-qPCR - reverse transcription quantitative polymerase chain reaction
SCC – squamous cell carcinoma
SEM – standard error of the mean
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SFM – serum-free media
TBS-T – Tris buffered saline + 0.1% Tween-20
TF – transcription factor
TGF-α – transforming growth factor alpha
URR – upstream regulatory region
WT – wild type
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Appendix B – Supplemental Xenograft Data

Supplemental Figure 1 Determination of epithelial area in SCC47 xenograft sections.
Scans of representative FFPE sections of xenografts from vehicle control tumors (top) and cetuximab
treated tumors (bottom). Unmarked scans of H&E stained sections are shown (left). Center images depict
scans of the same H&E slide with areas marked as epithelium (red), keratin (yellow), and stroma (green)
determined by morphology. Percent composition was determined for each tumor and averages are shown
in Fig. 4.3. Human mitochondrial marker IHC stained sections (right) were used to confirm epithelial
areas. All histology was performed by a certified pathologist (Dr. D. Kusewitt) using Aperio ImageScope
software.
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Supplemental Figure 2 Determination of epithelial area in SCC104 xenograft sections.
Scans of representative FFPE sections of xenografts from vehicle control tumors (top) and cetuximab
treated tumors (bottom). Unmarked scans of H&E stained sections are shown (left). Center images depict
scans of the same H&E slide with areas marked as epithelium (red), and stroma (blue) determined by
morphology. Percent composition was determined for each tumor and averages are shown in Fig. 4.8.
Human mitochondrial marker IHC stained sections (right) were used to confirm epithelial areas. All
histology was performed by a certified pathologist (Dr. D. Kusewitt) using Aperio ImageScope software.
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Supplemental Figure 3 Cetuximab treatment leads to lower levels of smooth muscle actin (SMA) in
tumor infiltrating fibroblasts.!
Tumor sections from NSG mice bearing xenograft tumors from SCC47 (A) or SCC104 (B) cell lines were
stained for SMA, a marker of activated tumor associated fibroblasts. Nuclei are stained with DAPI (blue)
and SMA is shown in red. Representative images are shown for each xenograft group. Percent of stroma
staining positive for SMA in sections from each tumor are shown in the graphs. Error bars = SEM,
statistical significance assessed by Student t-test, ***p≤0.001.
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Supplemental Table 1 Summary of SCC47 xenograft data
Average Untreated
Average Cetuximab
Tumor weight at necropsy (in
0.07
0.440
grams)
% Epithelium
39.25
15.23
% Necrosis
0
0
% Stroma
13.87
28.91
% SMA-positive stroma
92.50
14.00
% Keratin
38.66
45.69
EGFR IHC score
2.75
2.2
Phospho-EGFR IHC score
1.67
0.8
Phospho-ERK1/2 IHC score
3
1.6
Ki67-positive epithelium cells
21,633.75
1452.60
(total)
Ki67-positive cells (normalized to
784.55
760.96
epithelial area)
E6 relative RNA level
1.00
0.89
E7 relative RNA level
1.00
1.07
E6/E7 ISH
Staining sparse and
Strong staining in basal
low intensity
cells only, no staining in
upper epithelium
p16 IHC score
2.75
1.8
p53 IHC score
2.75
2
cFos relative RNA level
1.00
1.78
cFos:E6 Spearman’s r: -0.67
cFos:E7 Spearman’s r: -0.53
JunB relative RNA level
1
1.11
JunB:E6 Spearman’s r: -0.67
JunB:E7 Spearman’s r: -0.48
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Figure
4.2B
4.3
4.3
4.3
Supp. Fig. 3
4.3
4.4A
4.4B
4.4C
4.5C
4.5C
4.2C
4.2C
4.5D
4.5A
4.5B
4.2F
4.2G
4.2G
4.2F
4.2H
4.2H

Supplemental Table 2 Summary of SCC104 xenograft data
Average Untreated
Average Cetuximab
Tumor weight at necropsy (in
0.78
0.078
grams)
% Epithelium
30.23
54.45
% Necrosis
47.05
4.1
% Stroma
21.67
39.88
% SMA-positive stroma
98.00
25.00
% Keratin
0
0
EGFR IHC score
2
1.2
Phospho-EGFR IHC score
2
1.2
Phospho-ERK1/2 IHC score
1.25
0.8
Ki67-positive epithelium cells
36,315
4,333
(total)
Ki67-positive cells (normalized to
650
584
epithelial area)
E6 relative RNA level
1.00
6.52
E7 relative RNA level
1.00
9.13
E6/E7 ISH
High/Diffuse
High/Diffuse
p16 IHC score
3
2
p53 IHC score
0
0
cFos relative RNA level
1.00
0.73
cFos:E6 Spearman’s r: 0.88
cFos:E7 Spearman’s r: 0.78
JunB relative RNA level
1.00
1.12
JunB:E6 Spearman’s r: -0.32
JunB:E7 Spearman’s r: -0.45

Figure
4.7A, B
4.8
4.8
4.8
Supp. Fig. 3
4.8
4.9A
4.9B
4.9C
4.10C
4.10C
4.7C
4.7C
4.1D
4.10A
4.10B
4.7F
4.7G
4.7G
4.7F
4.7H
4.7H

B.1 Effect of Cetuximab Treatment on Viral Oncogene Expression in SiHa Tumor
Xenografts
SiHa cells contain 1.5 integrated copies of the HPV16 genome and whole genome
sequencing has shown that the intact LCR is still located upstream of viral genes [156].
A previous study found that cetuximab treatment reduces the growth rate of SiHa
xenografts in mice [194]. In our study, cetuximab (1mg/kg, 3x/week) treatment of mice
with SiHa xenografts resulted in diminished tumor growth and this was highly evident as
early as 2 weeks post treatment start (Supplemental Fig. 4A). Xenografts were harvested
at 6 weeks post treatment, when control tumors reached the maximum volume allowed in
our study. Cetuximab treated xenografts increased in size <2-fold from the starting
volume while tumors in the control group increased by an average of 15x their original
volume. E6 and E7 transcript levels in the xenograft tumors harvested at 6-weeks post
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treatment were evaluated by RT-qPCR and normalized to human β-actin expression
levels. Based on group averages, viral oncogene transcript levels were downregulated in
cetuximab treated xenografts but this difference was not statistically significant
(Supplemental Fig. 4B). When normalized levels of E6 and E7 transcripts were plotted
against the change in tumor volume over the course of treatment, we observed no
significant correlation between the levels of either E6 or E7 oncogene transcript and
tumor volume (Supplemental Fig. 4C). This suggests that final tumor size is not directly
associated with levels of viral oncogene expression. However, we cannot rule out a role
for cetuximab-mediated oncogene suppression in the antitumor effects seen. There may
be a threshold level of E6/E7 expression required to drive survival and or maintenance of
tumor size in SiHa xenografts treated with cetuximab.

In which case, the modest

downregulation of E6/E7 expression observed may have been enough to have a
significant impact on tumor growth rate.
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Supplemental Figure 4! Cetuximab delays tumor growth and decreases viral oncogene expression
along with c-Fos and JunB expression levels in SiHa xenografts.
NSG mice bearing SiHa xenografts implanted subcutaneously were given cetuximab (1 mg/kg) or vehicle
only (0.9% saline) by i.p injection 3x/week. Tumors were measured 3x/week by caliper and percent
growth from treatment start (time=0) are shown in (A). RNA from homogenized tumor sections was
analyzed by RT-qPCR for expression levels of viral oncogenes E6 and E7, and AP-1 transcription factors
cFos and JunB. Transcript levels were normalized to human β-actin transcript levels. The average
expression levels of normalized target from the vehicle tumors was set to 1 and data shown as fold-change
compared to control. Relative expression levels of E6 and E7 are shown in (B). Relative levels of E6 and
E7 transcripts were plotted against the change in tumor volume over the course of treatment and linear
correlation assessed by Spearman’s r test (C). Relative expression levels of c-Fos and JunB are shown in
(D). Relative levels of E6 and E7 transcripts were plotted against the expression levels of c-Fos (E) and
JunB (F) and linear correlation assessed by Spearman’s r test. Error bars = SEM, statistical significance
assessed by Student t-test, *p≤0.05, **p≤0.01, ***p≤0.001.

When the data in each group are averaged, expression of both cFos and JunB was
downregulated in cetuximab treated animals (Supplemental Fig. 4D). In each tumor, we
compared the levels of viral transcripts to the levels of AP-1 c-Fos and JunB RNA levels
and found there was a strong positive correlation between levels of c-Fos expression and
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E6 and E7 transcript levels in each tumor (E6: r=0.79, p≤0.01; E7: r=0.86, p≤0.001)
(Supplemental Fig. 4E) and a modest correlation between JunB and E6/E7 transcript
levels (E6: r=0.56, n.s.; E7: r=0.67, p≤0.01) (Supplemental Fig. 4F). These results
indicate that cetuximab treatment leads to reduced viral oncogene transcript levels in
SiHa xenografts, in agreement with our original hypothesis.

The concurrent

downregulation of transcript levels of AP-1 transcription factors c-Fos and JunB in
cetuximab treated cells suggest that these proteins may be associated with the diminished
E6 and E7 levels observed in these tissues. As noted previously, the integrated viral
genome has been reported to contain the intact LCR, containing AP-1 binding sites,
upstream of the E6 and E7 genes in SiHa cells indicating that this region may still control
viral transcription [156].

B.2 Effect of Cetuximab Treatment on Viral Oncogene Expression in CaSki Tumor
Xenografts
CaSki cells contain >800 integrated HPV16 genomes with numerous genomic
translocations ([156] and others). However, only one of the viral genomes, located on a
derivative of chromosome 14, is transcriptionally active [23].

There are two viral

genomes integrated within chromosome 14, the first contains a viral breakpoint within
the E6 gene and is therefore likely not the source of E6 and E7 expression [156]. The
second integrated genome is likely the transcriptionally active site observed previously
and it contains a breakpoint within the viral LCR, suggesting this region may not be
influencing viral oncogene transcription in this cell line. CaSki tumors grew faster than
SiHa xenografts and the tumors had to be harvested at 4 weeks post treatment start.
Cetuximab treatment resulted in 2.5x decreased tumor growth rate in CaSki xenografts as
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compared to the vehicle control group; however, this was less dramatic than in the SiHa
cohort (Supplemental Fig. 5A). We detected no change in E6 RNA expression levels
upon cetuximab treatment in CaSki xenografts (Supplemental Fig. 5B). Surprisingly,
levels of E7 increased while the tumors grew slowly following cetuximab treatment
(Supplemental Fig. 5B). The remarkably similar levels of E7 RNA found in cetuximab
treated, slow growing tumors might be indicative that there was a selection for cells with
higher E7 expression levels. Furthermore, there was a moderate negative correlation
between normalized levels E7 transcripts and change in tumor volume over the course of
treatment the tumors from the cetuximab treated group were expressing relatively higher
levels of E7 than those from the control group (Supplemental Fig. 5C). These results
suggest that the decrease in tumor growth rate is not associated with E6 and E7
expression levels.
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Supplemental Figure 5 Cetuximab produces antitumor effects independent of viral oncogene
expression in CaSki xenografts.
NSG mice bearing CaSki xenografts implanted subcutaneously were given cetuximab (1 mg/kg) or vehicle
only (0.9% saline) by i.p injection 3x/week. Tumors were measured 3x/week by caliper and percent growth
from treatment start (time=0) are shown in (A). RNA from homogenized tumor sections was analyzed by
RT-qPCR for expression levels of viral oncogenes E6 and E7, and AP-1 transcription factors cFos and
JunB. Transcript levels were normalized to human β-actin transcript levels. The average expression levels
of normalized target from the vehicle tumors was set to 1 and data shown as fold-change compared to
control. Relative expression levels of E6 and E7 are shown in (B). Relative levels of E6 and E7 transcripts
were plotted against the change in tumor volume over the course of treatment and linear correlation
assessed by Spearman’s r test (C). Relative expression levels of c-Fos and JunB are shown in (D). Relative
levels of E6 and E7 transcripts were plotted against the expression levels of c-Fos (E) and JunB (F) and
linear correlation assessed by Spearman’s r test. Error bars = SEM, Statistical significance assessed by
Student t-test, *p≤0.05.

We observed no statistically significant differences in c-Fos or JunB expression
between cetuximab and vehicle groups (Supplemental Fig. 5D). Neither did we find a
significant correlation between E6 or E7 transcript levels and either of the AP-1
transcription factors evaluated (Supplemental Fig. 5E, F). These data together suggest
that expression of c-Fos and JunB is not altered by EGFR inhibition. In fact, cetuximab
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treatment led to similarly increased E7 RNA levels in xenografts. Analysis of gene
expression profiles by RNAseq and proteomic profiling would be useful in better
understanding the signaling pathways differentially activated in this cell line.
Histological analysis of tumors from vehicle and treated animals will also be useful in
determining the mechanisms behind the reaction of these tumors specifically, it would be
important to determine if cetuximab treated tumors contain cells with sustained phosphoEGFR and heightened E7 expression.
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